Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Sep. 30, 2018	Dec. 14, 2018	Mar. 30, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	Outlook Therapeutics, Inc.
Entity Central Index Key	0001649989
Trading Symbol	ons
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--09-30
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		85,091,062
Entity Public Float			$ 15.6
Document Type	10-K
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true

Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Current assets:
Cash	$ 1,717,391	$ 3,185,519
Prepaid and other current assets	1,585,089	719,087
Total current assets	3,302,480	3,904,606
Property and equipment, net	18,489,976	16,088,902
Other assets	491,039	740,362
Total assets	22,283,495	20,733,870
Current liabilities:
Senior secured notes	13,179,449
Current portion of long-term debt	66,480	52,600
Current portion of capital lease obligations	520,794	341,120
Stockholder notes	4,612,500	4,612,500
Accounts payable	3,609,607	10,954,358
Accrued expenses	6,458,471	7,337,469
Income taxes payable	1,856,129	2,352,129
Deferred revenue	1,738,603	3,087,561
Total current liabilities	32,042,033	28,737,737
Senior secured notes		13,231,700
Long-term debt	98,487	151,110
Capital lease obligations	3,453,256	28,067
Warrant liability	1,227,225	2,274,954
Deferred revenue	2,758,262	4,466,865
Other liabilities	3,514,738	2,569,971
Total liabilities	43,094,001	51,460,404
Commitments (Note 9)
Convertible preferred stock:
Total convertible preferred stock	4,734,416	2,924,441
Stockholders' equity (deficit):
Series A preferred stock, par value $0.01 per share: 10,000,000 shares authorized, no shares issued and outstanding
Common stock, par value $0.01 per share; 200,000,000 shares authorized; 72,220,351 and 24,933,944 shares issued and outstanding at September 30, 2018 and 2017, respectively	722,204	249,339
Additional paid-in capital	190,040,237	152,315,088
Accumulated deficit	(216,307,363)	(186,215,402)
Total stockholders' equity (deficit)	(25,544,922)	(33,650,975)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	22,283,495	20,733,870
Series A convertible preferred stock
Convertible preferred stock:
Total convertible preferred stock		$ 2,924,441
Series A-1 convertible preferred stock
Convertible preferred stock:
Total convertible preferred stock	$ 4,734,416

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2018	Sep. 30, 2017
Series A preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Series A preferred stock, shares authorized	10,000,000	10,000,000
Series A preferred stock, shares issued	0	0
Series A preferred stock, shares outstanding	0	0
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares, issued	72,220,351	24,933,944
Common stock, shares, outstanding	72,220,351	24,933,944
Series A convertible preferred stock
Convertible stock, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible stock, shares authorized	1,000,000	1,000,000
Convertible stock, shares issued	0	32,628
Convertible stock, shares outstanding	0	32,628
Series A-1 Convertible Preferred Stock
Convertible stock, par value (in dollars per share)	$ 100.00	$ 100.00
Convertible stock, shares authorized	200,000	200,000
Convertible stock, shares issued	60,203	0
Convertible stock, shares outstanding	60,203	0

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Collaboration revenues	$ 3,087,560	$ 3,811,519
Operating expenses:
Research and development	18,504,035	23,809,749
General and administrative	14,227,828	15,882,033
Operating expenses total	32,731,863	39,691,782
Loss from operations	(29,644,303)	(35,880,263)
Interest expense, net	3,891,250	5,625,833
Loss on extinguishment of debt	1,252,353
Change in fair value of warrant liability	(1,047,729)	(3,158,469)
Loss before income taxes	(33,740,177)	(38,347,627)
Income tax (benefit) expense	(3,648,216)	501,500
Net loss	(30,091,961)	(38,849,127)
Recognition of beneficial conversion feature upon issuance of Series A and A-1 convertible preferred stock	(16,022,963)	(1,176,743)
Series A and A-1 convertible preferred stock dividends and related settlement	(1,903,930)
Net loss attributable to common stockholders	$ (48,018,854)	$ (40,025,870)
Per share information:
Net loss per share of common stock, basic (in dollars per share)	$ (1.22)	$ (1.67)
Net loss per share of common stock, diluted (in dollars per share)	$ (1.22)	$ (1.80)
Weighted average shares outstanding, basic (in shares)	39,457,664	24,022,371
Weighted average shares outstanding, diluted (in shares)	39,457,664	24,041,789

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Series A Convertible Preferred Stock	Series A-1 Convertible Preferred Stock	Series B Convertible Preferred Stock	Common stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2016				$ 228,028	$ 141,965,342	$ (147,366,275)	$ (5,172,905)
Balance (in shares) at Sep. 30, 2016				22,802,778
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from exercise of common stock warrants				$ 7,869	305,616		313,485
Proceeds from exercise of common stock warrants (in shares)				787,018
Issuance of vested restricted stock units				$ 4,840	(4,840)
Issuance of vested restricted stock units (in shares)				483,913
Issuance of common stock in connection with equity facility				$ 1,224	(1,224)
Issuance of common stock in connection with equity facility (in shares)				122,418
Sale of common stock, net of issuance costs				$ 7,378	1,495,749		1,503,127
Sale of common stock, net of issuance costs (in shares)				737,817
Sale of Series A convertible preferred, net of costs	$ 2,924,441
Sale of Series A convertible preferred, net of costs (in shares)	32,628
Series A convertible preferred stock dividends					(16,985)		(16,985)
Stock-based compensation expense					8,571,430		8,571,430
Net loss						(38,849,127)	(38,849,127)
Balance at Sep. 30, 2017	$ 2,924,441			$ 249,339	152,315,088	(186,215,402)	(33,650,975)
Balance (in shares) at Sep. 30, 2017	32,628			24,933,944
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from exercise of common stock warrants				$ 35	(35)
Proceeds from exercise of common stock warrants (in shares)				3,460
Issuance of vested restricted stock units				$ 8,429	(8,429)
Issuance of vested restricted stock units (in shares)				842,889
Private placement sale of common stock and common stock warrants, net of costs				$ 127,548	14,567,572		14,695,120
Private placement sale of common stock and common stock warrants, net of costs (in shares)				12,754,766
Sale of Series A convertible preferred stock and common stock warrants, net of costs	$ 14,265,861				6,382,181		6,382,181
Sale of Series A convertible preferred stock and common stock warrants, net of costs (in shares)	217,372
Series A convertible preferred stock dividends and related settlement	$ 1,757,093				(1,740,108)		(1,740,108)
Series A convertible preferred stock dividends and related settlement (in shares)	17,571
Conversion of Series A convertible preferred stock into common stock	$ (14,359,816)			$ 315,726	14,044,090		14,359,816
Conversion of Series A convertible preferred stock into common stock (in shares)	(208,836)			31,572,617
Conversion of Series A convertible preferred stock into Series A-1 convertible preferred stock	$ (4,587,579)	$ 4,587,579
Conversion of Series A convertible preferred stock into Series A-1 convertible preferred stock (in shares)	(58,735)	58,735
Series A-1 convertible preferred stock dividends and related settlement		$ 146,837			(146,837)		(146,837)
Series A-1 convertible preferred stock dividends and related settlement (in shares)		1,468
Conversion of senior secured notes into Series B convertible preferred stock			$ 2,661,972				2,661,972
Conversion of senior secured notes into Series B convertible preferred stock (in shares)			1,500,000
Conversion of Series B convertible preferred stock into common stock			$ (2,661,972)	$ 21,127	2,640,845
Conversion of Series B convertible preferred stock into common stock (in shares)			(1,500,000)	2,112,675
Stock-based compensation expense					1,985,870		1,985,870
Net loss						(30,091,961)	(30,091,961)
Balance at Sep. 30, 2018		$ 4,734,416		$ 722,204	$ 190,040,237	$ (216,307,363)	$ (25,544,922)
Balance (in shares) at Sep. 30, 2018		60,203		72,220,351

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Sep. 30, 2018	Sep. 30, 2017
OPERATING ACTIVITIES
Net loss	$ (30,091,961)	$ (38,849,127)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,054,352	2,692,100
Loss on extinguishment of debt	1,252,353
Non-cash interest expense	1,315,861	4,014,633
Stock-based compensation	1,985,870	8,571,430
Change in fair value of warrant liability	(1,047,729)	(3,158,469)
Loss on disposal of fixed assets		61,867
Loss on lease termination	4,173,682
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,419,551)	2,607,520
Other assets	1,554	112,439
Accounts payable	(6,714,137)	5,727,136
Accrued expenses	(1,664,843)	893,526
Income taxes payable	(496,000)	497,500
Deferred revenue	(3,057,561)	1,188,481
Other liabilities	(331,413)	135,910
Net cash used in operating activities	(33,039,523)	(15,505,054)
INVESTING ACTIVITIES
Purchase of property and equipment	(2,781,125)	(292,086)
Net cash used in investing activities	(2,781,125)	(292,086)
FINANCING ACTIVITIES
Proceeds from the sale of common stock, net of offering costs	14,695,120	1,607,396
Payment of debt issuance costs		(40,000)
Proceeds from issuance of Series A convertible preferred stock	21,737,200	3,262,800
Proceeds from the sale of senior secured notes and detachable warrants		15,000,000
Proceeds from exercise of common stock warrants		253,289
Change in restricted cash		216,086
Payments of capital leases obligations	(862,906)	(991,028)
Repayment of debt	(127,736)	(2,677,771)
Payment of financing costs	(1,089,158)
Net cash provided by financing activities	34,352,520	16,630,772
Net (decrease) increase in cash	(1,468,128)	833,632
Cash at beginning of year	3,185,519	2,351,887
Cash at end of year	1,717,391	3,185,519
Supplemental disclosure of cash flow information
Cash paid for interest	109,979	1,339,644
Cash paid for income taxes		1,500
Supplemental schedule of noncash investing activities:
Purchases of property and equipment in accounts payable and accrued expenses	816,501	68,507
Supplemental schedule of noncash financing activities:
Issuance of Series B convertible preferred stock upon conversion of senior secured notes, net of unamortized debt discount	1,409,619
Issuance of capital lease obligations and debt in connection with purchase of property and equipment	4,444,095	62,230
Series A and A-1 convertible preferred stock dividends	1,886,945	16,985
Settlement of Series A and A-1 convertible preferred stock dividends upon issuance of Series A and A-1 convertible preferred stock	$ 1,903,930
Deferred offering costs and common stock issuance costs in accounts payable and accrued expenses		$ 630,717

Liquidity	12 Months Ended
Liquidity	Sep. 30, 2018
Liquidity [Abstract]
Liquidity	2. Liquidity The Company has incurred substantial losses and negative cash flows from operations since its inception and has an accumulated deficit of $216.3 million as of September 30, 2018. The Company has substantial indebtedness that includes $13.5 million of senior secured notes that may become due in fiscal 2019 and $4.6 million of unsecured indebtedness, $1.0 million of which is due on demand, and $3.6 million of which matures December 22, 2018. There can be no assurance that the holders of the stockholder notes will not exercise their right to demand repayment. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. On November 5, 2018, the Company entered into a purchase agreement with BioLexis Pte. Ltd. (“BioLexis”), formerly known as GMS Tenshi Holdings Pte. Limited, a Singapore private limited company, and the Company’s controlling stockholder and strategic partner, providing for the private placement of $20.0 million of shares of its common stock at $0.9327 per share. The closing of the sale of the first two tranches of this private placement for an aggregate of 12,865,872 shares of the Company’s common stock for aggregate cash proceeds of $12.0 million occurred in November and December 2018. The remaining $8.0 is expected to be funded in two equal tranches on January 3, 2019 and February 1, 2019, subject to customary conditions and achieving certain funding milestones as set forth in the purchase agreement. The Company intends to use the net proceeds from the private placement primarily for clinical trials for its lead product candidate, ONS-5010, and for working capital and general corporate purposes, including the agreed repayments on the senior secured notes. Also on November 5, 2018, the Company reached an agreement with the holders of its $13.5 million senior secured notes to extend the maturity of the senior secured notes, up to 12 months, or until December 22, 2019, in exchange for making several payments of principal and interest through August 31, 2019, subject to meeting additional capital raising commitments, with an initial payment of $2.2 million paid on November 7, 2018. As of September 30, 2018, the senior secured notes remain classified as a current liability because raising additional capital is outside the Company’s control. In addition, the Company agreed to make the senior secured notes convertible into common stock at a price of $1.11924 per share (120% of the price per share paid by BioLexis under the purchase agreement) and reduced the exercise price of the warrants held by such holders to $1.50 and extended the expiration of these warrants by three years. On November 30, 2018, the Company received approval from the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer Program to sell approximately $3.7 million of its unused New Jersey net operating losses (“NOLs”) and research and development tax credits (“R&D credits”). The Company expects to receive approximately $3.4 million of proceeds from the sale of the New Jersey NOLs and R&D credits. Management believes that the Company’s existing cash as of September 30, 2018, additional $20.0 million funding from the November BioLexis private placement and anticipated proceeds from the sale of New Jersey NOLs and R&D credits will be sufficient to fund its operations into June 2019, excluding any unscheduled repayment of debt. Substantial additional financing will be needed by the Company to fund its operations in the future and to commercially develop its product candidates. Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include, but are not limited to: private placements of equity and/or debt, payments from potential strategic research and development partners, licensing and/or marketing arrangements with pharmaceutical companies, sale of its development stage product candidates to third parties and public or private offerings of equity and/or debt securities. There can be no assurance that these future funding efforts will be successful. The Company’s future operations are highly dependent on a combination of factors, including (i) the timely and successful completion of additional financing discussed above; (ii) the Company’s ability to complete revenue-generating partnerships with pharmaceutical companies; (iii) the success of its research and development; (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies, and, ultimately; (v) regulatory approval and market acceptance of the Company’s proposed future products.

Basis of Presentation and Summary of Significant Accounting Policies

12 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

3. Basis of Presentation and Summary of Significant Accounting Policies

Basis of presentation

The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements include the accounts of the Company and Outlook Therapeutics Pty Ltd, its wholly-owned subsidiary incorporated in Australia (the “Subsidiary”). All intercompany accounts and transactions have been eliminated in consolidation. The Company has determined the functional currency of the Subsidiary to be the U.S. dollar. The Company translates assets and liabilities of its foreign operations at exchange rates in effect at the balance sheet date. The Company records remeasurement gains and losses on monetary assets and liabilities, such as incentive and tax receivables and accounts payables, which are not in the functional currency of the operation. These remeasurement gains and losses are recorded in the consolidated statement of operations as they occur.

Use of estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.

Fair value of financial instruments

At September 30, 2018 and 2017, the Company’s financial instruments included accounts payable, accrued expenses, equipment loans, stockholder notes and senior secured notes. The carrying amount of accounts payable and accrued expenses approximates fair value due to the short-term maturities of these instruments.

Property and equipment

Expenditures for maintenance and repairs are expensed as incurred while renewals and betterments are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in operations.

Long-lived assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. The Company has not recognized any impairment of long-lived assets for the years ended September 30, 2018 and 2017.

Stock-based compensation

The Company measures equity classified stock-based awards granted to employees and directors based on the estimated fair value on the date of grant and recognizes compensation expense of those awards, on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model, which is described more fully in Note 12. The fair value of each restricted stock award is measured as the fair value per share of the Company’s common stock on the date of grant.

Stock-based awards granted to consultants and non-employees are measured based on the fair value of the award on the date on which the related services are completed. Compensation expense is recognized over the period during which services are rendered by such consultants and non-employees until completed. At the end of each financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then-current fair value of the Company’s common stock and updated assumption inputs in the Black-Scholes option-pricing model.

Revenue recognition

The Company’s revenue is generated primarily through collaboration research and license agreements. The terms of these agreements generally contain multiple deliverables which may include (i) licenses, (ii) research and development activities, (iii) clinical manufacturing and (iv) product supply. The payment terms of these agreements may include nonrefundable upfront fees, payments for research and development activities, payments based upon the achievement of certain milestones, royalty payments based on product sales derived from the collaboration, and payments for supplying product.

The Company considers whether the deliverables under the arrangement represent separate units of accounting. In determining the units of accounting, management evaluates certain criteria, including whether the deliverables have stand-alone value. The consideration received is allocated to the separate units of accounting using the relative selling price method, and the applicable revenue recognition criteria are applied to each of the separate units.

The Company typically receives upfront, nonrefundable payments when licensing its intellectual property. For intellectual property licenses that do not have stand-alone value from the other deliverables to be provided, the upfront fee is deferred and revenue is recognized over the contractual or estimated performance period, which is typically the term of the research and development obligations. The periods over which revenue is recognized are subject to estimates by management and may change over the course of the research and development agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Payments or reimbursements resulting from the Company’s research and development efforts are recognized as the services are performed. Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue.

The Company recognizes revenue from milestone payments when: (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, and (ii) the Company does not have ongoing performance obligations related to the achievement of the milestone earned. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment (a) is commensurate with either the Company’s performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the Company’s performance to achieve the milestone, (b) relates solely to past performance, and (c) is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement.

Incentive and tax receivables

The Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, the Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by the Subsidiary in Australia. The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period. The Company’s estimate of the amount of cash refund it expects to receive related to the Australian research and development tax incentive program is included in prepaid and other current assets in the accompanying consolidated balance sheet. As of September 30, 2018, the Company’s estimate of the amount of cash refund it expects to receive in 2019 for 2018 eligible spending as part of this incentive program was $0.3 million.

In addition, the Subsidiary incurs Goods and Services Tax (“GST”) on services provided by Australian vendors. As an Australian entity, the Subsidiary is entitled to a refund of the GST paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST incurred is included in prepaid and other current assets in the accompanying consolidated balance sheet. As of September 30, 2018, prepaid and other current assets included $0.1 million for refundable GST on expenses incurred with Australian vendors.

Research and development

Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs.

Upfront milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. Research and development expenses are recorded net of expected refunds of eligible research and development costs paid to Australian vendors pursuant to the Australian research and development tax incentive program and GST incurred on services provided by Australian vendors. During the year ended September 30, 2018, the Company recorded $0.3 million in its consolidated results of operations related to the cash refund it expects to receive from the Australian research and development tax incentive program.

Income taxes

The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Net loss per share

Basic net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period.

For purposes of calculating diluted net loss per common share, the denominator includes both the weighted-average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards using the treasury stock method. The diluted net loss per common share calculation is further affected by an add-back of change in fair value of warrant liability to the numerator under the assumption that the change in fair value of warrant liability would not have been incurred if the warrants had been converted into common stock.

The following table sets forth the computation of basic earnings per share and diluted earnings per share:

	Year Ended September 30,
	2018			2017
Basic Earnings Per Share
Net loss attributable to common stockholders		$	(48,018,854)		$	(40,025,870)
Common stock outstanding (weighted average)			39,457,664			24,022,371
Basic net loss per share		$	(1.22)		$	(1.67)
Diluted Earnings Per Share
Net loss attributable to common stockholders		$	(48,018,854)		$	(40,025,870)
Add change in fair value of warrant liability			—			(3,158,469)
Diluted net loss			(48,018,854)			(43,184,339)
Common stock outstanding (weighted average)			39,457,664			24,022,371
Add shares from dilutive warrants			—			19,418
Common stock equivalents			39,457,664			24,041,789
Diluted net loss per share		$	(1.22)		$	(1.80)

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September 30, 2018 and 2017, as they would be antidilutive:

	As of September 30,
	2018		2017
Series A-1 convertible preferred stock		9,101,717		—
Performance-based stock units		129,095		175,530
Restricted stock units		61,109		939,879
Stock options		1,557,145		—
Common stock warrants		45,292,532		7,484,504

Recently issued accounting pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09) and has subsequently issued a number of amendments to ASU 2014-09. The new standard, as amended, provides a single comprehensive model to be used in the accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific guidance. The standard’s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASU 2014-09 includes provisions within a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

The new standard will be effective for the Company beginning October 1, 2018 and permits two methods of adoption: the full retrospective method, which requires the standard to be applied to each prior period presented, or the modified retrospective method, which requires the cumulative effect of adoption to be recognized as an adjustment to opening retained earnings in the period of adoption. The Company will adopt the standard using the modified retrospective method.

The Company’s arrangements fall under ASC 808, Collaborations, (“ASC 808”). ASC 808 does not address recognition or measurement matters but prescribes that entities look to other GAAP by analogy, namely ASU 2014-09. As such, the Company has completed an analysis of existing contracts with the Company’s collaboration partners and assessed the differences in accounting for such contracts under ASU 2014-09 compared with current revenue accounting standards. Based on the review of current contracts, the Company expects an adjustment to increase accumulated deficit related to substantive milestones that were previously recognized under current revenue guidance in the period the milestone was achieved. ASU 2014-09 prescribes that those milestones are a form of variable consideration and should be recognized when the performance obligation is satisfied. Although the Company is still finalizing the impact to the consolidated financial statements as of October 1, 2018, the Company expects the adjustment to be an increase to accumulated deficit of approximately $3.6 million.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASC 842”). The FASB issued subsequent amendments to the initial guidance in July 2018 with ASU 2018-10 and in August 2018 with ASU 2018-11. ASC 842 supersedes the current accounting for leases. The new standard requires lessees to record a right of use asset and a related liability for the rights and obligations associated with a lease, regardless of lease classification, and eliminates the required use of bright-line tests in current U.S. GAAP for determining lease classification. This ASU is effective for annual periods beginning after December 15, 2018 (i.e., calendar periods beginning on January 1, 2019), and interim periods thereafter. Earlier application is permitted for all entities, however the Company does not plan to early adopt. The new standard must be adopted using either the modified retrospective approach, which requires application of the new guidance at the beginning of the earliest comparative period presented or the optional alternative approach, which requires application of the new guidance at the beginning of the standard’s effective date. The Company has arrangements currently classified as operating leases which will be recorded as a right of use asset and corresponding liability on the balance sheet and is currently evaluating the impact these changes will have on the consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting. This new ASU is intended provide clarity and reduce both the diversity in practice of and cost and complexity of applying the guidance in Topic 718, Compensation — Stock Compensation, to a change to the terms or conditions of a share-based payment award. This ASU provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This ASU is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“Topic 718”), which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The standard will be effective for fiscal years beginning after December 15, 2018, although early adoption is permitted (but no sooner than the adoption of Topic 606). This ASU is not expected to have a material impact on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement, which removes and modifies some existing disclosure requirements and adds others. The ASU is effective for all entities for fiscal years beginning after December 15, 2019, including interim periods therein. Early adoption is permitted for any eliminated or modified disclosures upon issuance of this ASU. The Company is currently evaluating when to adopt this standard.

Fair Value Measurements

12 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

• Level 1 — Quoted prices in active markets for identical assets or liabilities.

• Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

• Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis:

	September 30, 2018
	(Level 1)			(Level 2)			(Level 3)
Liabilities
Warrant liability		$	—		$	—		$	1,227,225

	September 30, 2017
	(Level 1)			(Level 2)			(Level 3)
Liabilities
Warrant liability		$	—		$	—		$	2,274,954

The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuation for the warrant liability for the years ended September 30, 2018 and 2017:

Balance at October 1, 2016	$	—
Issuance of warrants		5,493,619
Exercise of warrants		(60,196)
Change in fair value		(3,158,469)
Balance at September 30, 2017		2,274,954
Change in fair value		(1,047,729)
Balance at September 30, 2018	$	1,227,225

The Senior Note Warrants issued in connection with the Notes (see Note 8) are classified as liabilities on the accompanying consolidated balance sheet as the Senior Note Warrants include cash settlement features at the option of the holders under certain circumstances. The warrant liability is revalued each reporting period with the change in fair value recorded in the accompanying consolidated statements of operations until the warrants are exercised or expire. The fair value of the warrant liability is estimated using the Black-Scholes option pricing model using the following assumptions:

	September 30,
	2018	2017
Risk-free interest rate	2.90%	1.77%
Remaining contractual life of warrant	3.39 years	4.67 years
Expected volatility	82%	82%
Annual dividend yield	0%	0%
Fair value of common stock	$0.98 per share	$1.37 per share

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property and Equipment

12 Months Ended

Sep. 30, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment

5. Property and Equipment

Property and equipment, net, consists of:

	September 30,
	2018			2017
Laboratory equipment		$	14,333,624		$	11,574,473
Leasehold improvements			10,095,100			10,032,640
Computer software and hardware			483,807			472,054
Land and building			3,000,000			—
Construction in progress			2,276,737			2,654,675
			30,189,268			24,733,842
Less: accumulated depreciation and amortization			(11,699,292)			(8,644,940)
		$	18,489,976		$	16,088,902

Depreciation and amortization expense for the years ended September 30, 2018 and 2017 was $3,054,352 and $2,692,100, respectively.

At September 30, 2018, $7,953,856 represents laboratory equipment under capital leases and the Company’s corporate office that is classified as a capital lease. At September 30, 2017, $3,692,913 represents laboratory equipment under capital leases. At September 30, 2018 and 2017, $1,619,741 and $1,061,901, respectively, of accumulated amortization related to capital leases. The term of the equipment leases are between 12 and 36 months and qualify as capital leases. The equipment leases bear interest between 4.0% and 19.4% and the effective interest rate on the corporate office lease is 43.9%.

In February 2018, the Company entered into a sixth amendment to its lease for its corporate offices. Pursuant to the amended terms, the Company is now occupying 100% of the corporate facility and has extended the term through February 2028 with two five year renewal options. As a result of this amendment, the lease is now classified as a capital lease. The Company initially recorded the lease obligation and corresponding building asset based on its estimated fair value of $3,000,000. The building is being depreciated over the lease term. Future lease payments will be allocated to interest expense and a pay-down of the lease obligation.

The following is a schedule of future minimum lease payments under capital leases as of September 30, 2018 for the years ending September 30:

2019	$	1,947,199
2020		1,594,917
2021		1,493,442
2022		1,522,660
2023		1,550,878
Thereafter		7,280,400
		15,389,496
Less: amounts representing interest		(11,415,446)
Less: current portion		(520,794)
Capital lease obligations, excluding current portion	$	3,453,256

Debt

12 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Debt

8. Debt

Senior secured notes

	September 30,
	2018			2017
Senior secured notes		$	13,500,000		$	15,000,000
Unamortized debt discount			(320,551)			(1,768,300)
		$	13,179,449		$	13,231,700

In October, November and December 2016, the Company issued $1.85 million aggregate principal amount of unsecured bridge notes to accredited investors. These unsecured notes bore interest at a rate of 15% per year and had a one-year maturity date from the date of issuance. The unsecured notes were exchanged for senior secured promissory notes in December 2016 as described below.

In December 2016, the Company entered into a Note and Warrant Purchase Agreement (the “NWPA”) with accredited investors providing for the issuance and sale of up to $10.0 million of senior secured promissory notes (the “Notes”), which bear interest at a rate of 5% per year and mature December 22, 2017 and warrants (the “Senior Note Warrants”) to acquire an aggregate 2.3 million shares of the Company’s common stock at an exercise price of $3.00 per share, which have a five-year term. The Company closed the initial sale and purchase of the Notes and Senior Note Warrants in December 2016, issuing $8.35 million aggregate principal amount of Notes and Senior Note Warrants to acquire up to 1,920,500 shares of the Company’s common stock in exchange for $6.5 million of cash and an aggregate of $1.85 million of existing unsecured bridge notes issued by the Company in October, November and December 2016. The proceeds were first allocated to the warrant liability based on an initial fair value of $3.3 million with a corresponding amount recorded as a debt discount. In addition, the Company incurred $40,000 of debt issuance costs that have been recorded as a debt discount. The debt discount is being amortized into interest expense over the term of the Notes using the effective interest method.

In January 2017, the Company issued additional Notes and Senior Note Warrants for $1.65 million of cash.

In April 2017, the Company entered into the First Amendment to the NWPA (the “Amendment”) with the required holders of its Notes named therein, to amend certain terms of the NWPA. The primary purpose of the Amendment was to increase the aggregate principal amount of Notes that may be sold under the NWPA from $10.0 million to $15.0 million, and permit the issuance of additional Senior Note Warrants to acquire an aggregate 1,665,000 shares of the Company’s common stock and extend the time that the Company may issue additional Notes and Senior Note Warrants without approval of the holders of existing notes from 90 days to 180 days. Notes sold under the Amendment bear interest at a rate of 5% per annum and were due to mature in December 2017. In September 2017, in connection with the Private Placement, the maturity date of the Notes was extended by one year to December 2018.

During April and May 2017, the Company issued an additional $5.0 million of Notes and Senior Note Warrants to acquire an aggregate of 1,304,500 shares of its common stock. The proceeds were first allocated to the warrant liability based on an initial fair value of $1.4 million with a corresponding amount recorded as a debt discount. In addition, the Company incurred $3,635 of debt issuance costs that have been recorded as a debt discount. The debt discount is being amortized into interest expense over the term of the Notes using effective interest rate method.

Under the NWPA and the Amendment, the Company agreed to customary negative covenants restricting its ability to repay indebtedness to officers, pay dividends to stockholders, repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of the Company’s assets, other than as permitted, or enter into any transactions with affiliates. In addition to the negative covenants in the NWPA, the Notes include customary events of default. In connection with the closing of the initial sale of the Notes and Senior Note Warrants, the Company entered into a Security Agreement and an Intellectual Property Security Agreement, each dated December 22, 2016, granting the holders of the Notes a security interest in all of its assets, as well as a Registration Rights Agreement dated February 3, 2017.

In September 2017, the Company entered into a purchase and exchange agreement (the “Exchange Agreement”) with two existing investors and holders of its senior secured notes (the “Noteholders”), pursuant to which the Noteholders exchanged $1.5 million aggregate principal amount of senior secured notes for 1,500,000 shares of Series B convertible preferred stock (“Series B Convertible”) and $41,507 of accrued interest on such exchanged senior secured notes in October 2017. The Company recognized a loss on extinguishment of $1,252,353 in connection with the exchange and represents the excess fair value of the Series B Convertible issued over the net carrying amount of the debt and accrued interest. The 1,500,000 shares of Series B Convertible were converted into an aggregate of 2,112,675 shares of common stock in June 2018 and there are no longer any shares of Series B Convertible issued and outstanding.

In connection with the November 2018 purchase agreement with BioLexis providing for the private placement of $20.0 million of shares of the Company’s common stock, the Company reached an agreement with the holders of the Notes to further extend the maturity of the Notes up to 12 months, or until December 22, 2019, in exchange for making several payments of principal and interest through August 31, 2019, subject to meeting additional capital raising commitments, of which $2.2 million was paid in November 2018 and $1.17 million was paid in December 2018. At September 30, 2018, the Notes remained classified as a current liability because raising additional capital is outside the Company’s control. In addition, the Company agreed to make the Notes convertible into common stock at a price of $1.11924 per share and reduced the exercise price of the Senior Note Warrants to $1.50 and extended the expiration of the Senior Note Warrants by three years.

Interest expense on the Notes for the years ended September 30, 2018 and 2017 was $1,997,231 and $4,441,886, respectively.

Other indebtedness

In addition to the Notes, the Company has other outstanding debt consisting of equipment loans and unsecured notes. Refer to Note 7 for additional information on unsecured notes.

	September 30,
	2018			2017
Equipment loans		$	164,967		$	203,710
Less: current portion			(66,480)			(52,600)
Long-term debt		$	98,487		$	151,110

The equipment loans bear interest at rates ranging from 12% to 16% with the original term of the loans ranging from 1 to 5 years. Minimum monthly payments of principal and interest under the equipment loans are collateralized by the related equipment purchased and an unconditional personal guarantee by the founding stockholder and former chief executive officer.

Interest expense on the above loans for the years ended September 30, 2018 and 2017 was $27,660 and $35,608, respectively.

Future maturities of other indebtedness at September 30, 2018 are as follows for the years ending September 30:

2019	$	66,480
2020		48,204
2021		50,283
	$	164,967

Commitments

12 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments

9. Commitments

Selexis Commercial License Agreements

In April 2013, the Company entered into commercial license agreements with Selexis for each of the ONS-3010, ONS-1045 and ONS-1050 biosimilar product candidates (which agreements were subsequently amended on May 21, 2014). Under the terms of each commercial license agreement, the Company acquired a non-exclusive worldwide license under the Selexis Technology to use the applicable Selexis expression technology along with the resulting Selexis materials/cell lines, each developed under the research license, to manufacture and commercialize licensed and final products, with a limited right to sublicense.

The Company paid an upfront licensing fee to Selexis for each commercial license and also agreed to pay a fixed milestone payment for each licensed product. In addition, the Company is required to pay a low single-digit royalty on a final product-by-final product and country-by-country basis, based on worldwide net sales of such final products by the Company or any of the Company’s affiliates or sublicensees during the royalty term. The royalty term for each final product in each country is the period commencing from the first commercial sale of the applicable final product in the applicable country and ending on the expiration of the specified patent coverage. At any time during the term, the Company has the right to terminate its royalty payment obligation by providing written notice to Selexis and paying Selexis a royalty termination fee.

Each of the Company’s commercial agreements with Selexis will expire upon the expiration of all applicable Selexis patent rights. Either party may terminate the related agreement in the event of an uncured material breach by the other party or in the event the other party becomes subject to specified bankruptcy, winding up or similar circumstances. Either party may also terminate the related agreement under designated circumstances if the Selexis Technology infringes third-party intellectual property rights. In addition, the Company has the right to terminate each of the commercial agreements at any time at its convenience; however, with respect to the agreements relating to ONS-3010 and ONS-1045, this right is subject to the licensee’s consent pursuant to a corresponding letter the Company executed in conjunction with the standby agreement entered into between Selexis and Laboratories Liomont, S.A. de C.V. (“Liomont”) in November 2014.

The standby agreement permits Liomont to assume the license under the applicable commercial agreement for Mexico upon specified triggering events involving the Company’s bankruptcy, insolvency or similar circumstances.

MTTR — Strategic partnership agreement (ONS-5010)

In February 2018, the Company entered into a strategic partnership agreement with MTTR, LLC, or MTTR, to advise on regulatory, clinical and commercial strategy and assist in obtaining approval of ONS-5010, the Company’s bevacizumab therapeutic product candidate for ophthalmic indications. Under the terms of the agreement, the Company currently pays MTTR a $58,333 monthly consulting fee. Beginning January 2019, the monthly fee increases to $105,208 per month, and then, after launch of ONS-5010 in the United States, to $170,833 per month (the amount of which is reduced by 50% in the event net sales of ONS-5010 are below a certain threshold million per year). The Company also agreed to pay MTTR a tiered percentage of the net profits of ONS-5010 ranging in the low- to mid-teens, with the ability to credit monthly fees paid to MTTR. In March 2018, the Company amended the MTTR agreement and agreed to pay a one-time fee of $268,553 to MTTR by September 2020 if certain regulatory milestones are achieved earlier than anticipated. For the year ended September 30, 2018, MTTR earned an aggregate of $602,629, which includes monthly consulting fees, expense reimbursement and an initial upfront payment of $75,000.

Technology license

The Company entered into a technology license agreement with Selexis that will require milestone payments of $353,600 (based on an exchange rate on September 30, 2018 for converting Swiss Francs to U.S. dollars) to the licensor by the Company upon achievement of certain clinical milestones and pay a single digit royalty on net sales by the Company utilizing such technology. The Company also has the contractual right to buy out the royalty payments at a future date.

Leases

In August 2015, the Company entered into a lease for approximately 82,000 square feet of office and laboratory space in Cranbury, New Jersey, with lease payments that commenced in March 2016 and was due to expire in March 2026. Due to the Company’s involvement in the construction required to complete the leased facility, the lease was accounted for as a financing arrangement to which the Company recorded the fair value of the asset in property and equipment and a corresponding liability was recorded and amortized over the lease term down to the expected asset value at the end of the lease. During the years ended September 30, 2018 and 2017, the Company recorded interest expense of $390,793 and $421,028, respectively.

In August 2018, the Company entered into a lease termination agreement effective September 1, 2018, to terminate the lease for office and laboratory space in Cranbury, New Jersey. In consideration for the termination of the lease, the Company agreed to make payments to the landlord totaling up to $5.8 million, which includes (i) $287,615 upon execution of the termination agreement, (ii) $50,000 per month for up to 30 months, commencing September 1, 2018, and (iii) a $4.0 million payment, in any event, on or before February 1, 2021. The Company and landlord agreed that the $174,250 security deposit will be used to pay the 7th, 8th, 9th and a portion of the 10th monthly payments. The Company may pay the final $4.0 million payment at any time, whereupon the Company’s obligation to make the remaining monthly payments terminates.

In connection with the lease termination, the Company recorded a $4.2 million liability at September 1, 2018, the cease-use date, that represents the present value of the future termination payments. The Company derecognized the assets and liabilities associated with the financing lease and recorded a charge of $4.2 million to general and administrative expense. At September 30, 2018, the current portion of the lease termination obligation of $395,071 is included in accrued expenses and $3,455,010 is included in other liabilities on the consolidated balance sheets. A rollforward of the charges incurred to general and administrative expense for the year ended September 30, 2018 is as follows:

	Balance October 1, 2017			Expensed/ Accrued Expense			Cash Payments			Non-Cash Items			Balance September 30, 2018
Lease termination payments		$	—		$	4,187,696		$	(337,615)		$	—		$	3,850,081
Derecognition of assets and liabilities			—			(14,014)			—			14.014			—
		$	—		$	4,173,682		$	(337,615)		$	14,014		$	3,850,081

Rent expense under operating leases was $854,487 and $1,352,708 for the years ended September 30, 2018 and 2017, respectively. The Company recognizes rent expense on a straight-line basis over the lease period and has accrued for rent expense incurred but not yet paid. Landlord allowances for tenant improvements are deferred and recognized as a reduction to rent expense on a straight line basis and over the remaining lease term.

Future minimum payments under noncancelable operating leases at September 30, 2018 are as follows for the years ending September 30:

	Operating Leases
2019		$	180,000
2020			187,500
2021			195,000
		$	562,500

Employee Benefit Plan

The Company maintains a defined contribution 401(k) plan in which employees may contribute up to 100% of their salary and bonus, subject to statutory maximum contribution amounts. The Company matches 100% of the first 3% of employee contributions. The Company assumes all administrative costs of the Plan. For the years ended September 30, 2018 and 2017, the expense relating to the matching contribution was $175,693 and $209,782, respectively.

Stockholders' Equity (Deficit)

12 Months Ended

Sep. 30, 2018

Stockholders' Equity Note [Abstract]

Stockholders' Equity (Deficit)

10. Stockholders’ Equity (Deficit)

Lincoln Park Capital, LLC transaction

In March 2017, the Company entered into a Purchase Agreement and a registration rights agreement with an accredited investor, Lincoln Park Capital, LLC (“Lincoln Park”), providing for the purchase of up to $15.4 million of the Company’s common stock over the 30-month term of the purchase agreement.

In connection with the purchase agreement, the Company issued 113,205 shares of its common stock as initial commitment shares, to Lincoln Park and the Company will issue, pro rata, up to an additional 113,206 shares of its common stock as additional commitment shares to Lincoln Park in connection with any additional purchases.

Under the terms and subject to the conditions of the purchase agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to an additional $15.0 million of shares of the Company’s common stock. As contemplated by the purchase agreement, and so long as the closing price of the Company’s common stock exceeds $1.50 per share, the Company may direct Lincoln Park, at the Company’s sole discretion to purchase up to 30,000 shares of its common stock on any business day. The price per share for such purchases will be equal to the lower of: (i) the lowest sale price on the applicable purchase date and (ii) the arithmetic average of the three (3) lowest closing sale prices for the Company’s common stock during the ten (10) consecutive business days ending on the business day immediately preceding such purchase date (in each case, to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction that occurs on or after the date of the purchase agreement). The maximum amount of shares subject to any single regular purchase increases as the Company’s share price increases, subject to a maximum of $1.0 million.

In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional purchases if the closing sale price of the common stock exceeds certain threshold prices as set forth in the purchase agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 4.99% of its common stock. There are neither trading volume requirements nor restrictions under the purchase agreement nor upper limits on the price per share that Lincoln Park must pay for shares of common stock.

The purchase agreement and the registration rights agreement contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of the parties. The Company has the right to terminate the purchase agreement at any time, at no cost or penalty. During any “event of default” under the purchase agreement, all of which are outside of Lincoln Park’s control, Lincoln Park does not have the right to terminate the purchase agreement; however, the Company may not initiate any regular or other purchase of shares by Lincoln Park, until such event of default is cured. In addition, in the event of bankruptcy proceedings by or against the Company the purchase agreement will automatically terminate.

During the year ended September 30, 2017, the Company sold 737,817 shares of common stock to Lincoln Park for $1,620,931, and incurred $147,540 of issuance costs. In addition, the Company issued 122,418 shares of common stock to Lincoln Park as commitment shares pursuant to the purchase agreement. There were no shares sold to Lincoln Park during the year ended September 30, 2018.

Common stock

In May 2018, the Company entered into a purchase agreement with BioLexis, pursuant to which BioLexis purchased, in a private placement, 12,754,766 shares of common stock and common stock warrants to purchase 20,512,820 shares of common stock for cash proceeds of $15.0 million. The transaction closed in two tranches in May and June 2018. The warrants have an exercise price of $0.975 per share and a term of eight years from their issuance date.

During the years ended September 30, 2018 and 2017, the Company issued 842,889 and 483,913 shares of common stock upon the vesting of RSUs, respectively.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company’s board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. No dividends had been declared through September 30, 2018.

Common stock warrants

As of September 30, 2018, the Company had the following warrants outstanding to acquire shares of its common stock:

Outstanding	Exercise Price Per Share			Expiration Date
3,333,333		$	6.60	February 18, 2019(i)
814,378		$	0.01	November 11, 2019
3,882,001		$	3.00	December 22, 2021(ii)
16,750,000		$	0.90	October 31, 2025
10,256,410		$	0.975	May 10, 2026
10,256,410		$	0.975	June 8, 2026
45,292,532

(i) In connection with the November 2018 purchase agreement with BioLexis providing for the private placement of $20.0 million of shares of the Company’s common stock, the Company undertook to take such action as necessary to reduce the exercise price of the Series A warrants to $1.50 and extend the expiration date of such Series A warrants by three years.

(ii) In November 2018, the Company reduced the exercise price of the Senior Note Warrants to $1.50 and extended the expiration of the Senior Note warrants by three years. Such Senior Note Warrants now expire eight years from their initial issuance date.

During the year ended September 30, 2018, warrants to purchase 3,460 shares with an exercise price of $0.01 were exercised. During the year ended September 30, 2017, warrants to purchase 704,019 and 82,999 shares with exercise prices of $0.01 and $3.00 per share respectively, were exercised.

Convertible Preferred Stock	12 Months Ended
Convertible Preferred Stock	Sep. 30, 2018
Equity [Abstract]
Convertible Preferred Stock	11. Convertible Preferred Stock Series A Convertible Preferred Stock In September 2017, the Company entered into a purchase agreement with BioLexis, pursuant to which BioLexis agreed to purchase, in a private placement (the “Initial Private Placement”), $25.0 million of the Company’s newly-created voting Series A Convertible Preferred Stock (the “Series A Convertible”), and warrants (the “BioLexis Warrants” and together with the Series A Convertible, the “Securities”) to acquire 16,750,000 shares of common stock. In September 2017, the Company completed the initial sale of 32,628 shares of Series A Convertible to BioLexis for $3,262,800 in cash. In October 2017, the Company completed the sale of the remaining 217,372 shares of Series A Convertible and the BioLexis Warrants to BioLexis in the Initial Private Placement, for $21,737,200 in cash. The Series A Convertible was initially convertible into 37,795,948 shares of the Company’s common stock, representing an effective conversion rate of $0.66 per share, which represented a discount to the market value of the Company’s common stock as of September 7, 2017 and October 31, 2017 (on which dates, the closing price of the Company’s common stock was $0.90 and $1.26 per share, respectively). In connection with the second closing of the Series A Convertible in October 2017, the Company issued the BioLexis Warrants, which have a term of 8-years and an initial exercise price of $0.90 per share. The proceeds from the second closing of the Series A Convertible were allocated among the Series A Convertible and the BioLexis Warrants based on their relative fair values. As a result of the discount to the market value and the allocation of a portion of the proceeds to the BioLexis Warrants, the Company recognized a beneficial conversion charge of $15,355,019, which represents the in-the-money value of the conversion rate as of the date of sale. The Series A Convertible accrued dividends at a rate of 10% per annum, compounded quarterly, payable quarterly at the Company’s option in cash or in kind in additional shares of Series A Convertible, although the initial dividends payable on the shares of Series A Convertible issued in September 2017, while accruing from issuance, was payable in December 2017. The Series A Convertible was also entitled to dividends on an as-if-converted basis in the same form as any dividends actually paid on shares of common stock or other securities. The initial conversion rate was subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the common stock. During the year ended September 30, 2018, the Company issued an additional 17,571 shares of Series A Convertible to settle the related dividends that were due on a quarterly basis. The Company recognized a beneficial conversion charge of $597,255 during the year ended September 30, 2018, which represents the in-the-money value of the conversion rate as of the date of issuance. In June 2018, BioLexis converted 208,836 shares of Series A Convertible into 31,572,617 shares of common stock, and in July 2018 exchanged its remaining shares of Series A Convertible for newly created Series A-1 (as defined below). As of such exchange, there were no longer any shares of Series A Convertible issued and outstanding. Series A-1 Convertible Preferred Stock In July 2018, the Company entered into an exchange agreement (the “Exchange Agreement”) with Biolexis, pursuant to which the Company exchanged 58,735 shares of voting Series A Convertible held by BioLexis for 58,735 shares of its newly created series of voting convertible preferred stock, voting Series A-1 Convertible Preferred Stock, (the “Series A-1”). Accordingly, all of the issued Series A Convertible have been retired and cancelled and may not be reissued as shares of such series in accordance with their terms. In connection with the entry into the Exchange Agreement, the Company and BioLexis amended the Investor Rights Agreement dated September 11, 2017, as amended, (the “Second Amendment to Investor Rights Agreement”) in order to provide the Investor certain registration and other rights with respect to the shares of Common Stock to be acquired upon conversion of the Series A-1 issued pursuant to the Exchange Agreement. A total of 200,000 shares of Series A-1 have been authorized for issuance under the Certificate of Designation of Series A-1 Convertible Preferred Stock of the Company. The shares of Series A-1 have a stated value of $100.00 per share, are initially convertible into 8,879,780 shares of the Common Stock and rank senior to all junior securities (as defined in the Certificate of Designation). The Series A-1 accrue dividends at a rate of 10% per annum, compounded quarterly, payable quarterly at the Company’s option in cash or in kind in additional shares of Series A-1. The Series A-1 is also entitled to dividends on an as-if-converted basis in the same form as any dividends actually paid on shares of Common Stock or other securities. The initial conversion rate is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Common Stock. The holders of the Series A-1 have the right to vote on matters submitted to a vote of the Company’s stockholders on an as-converted basis, voting with the Company’s other stockholders as a single class. In addition, without the prior written consent of a majority of the outstanding shares of Series A-1, the Company may not take certain actions, including amending its certificate of incorporation or bylaws, or issuing securities ranking pari passu or senior to the Series A-1. During the year ended September 30, 2018, the Company issued 1,468 shares of Series A-1 Convertible to settle the related dividends that are due on a quarterly basis. The Company recognized a beneficial conversion charge of $70,662 during the year ended September 30, 2018, which represents the in-the-money value of the conversion rate as of the date of issuance. The terms of the Series A-1 distinguish between certain liquidation events (such as a voluntary or involuntary liquidation, dissolution or winding up of the Company) and “deemed” liquidation events (such as a sale of all or substantially all of the Company’s assets, various merger and reorganization transactions, being delisted from Nasdaq, and the occurrence of an event of default under the terms of the senior secured notes), in each case as defined in the Certificate of Designation. In the event of a liquidation (as defined in the Certificate of Designation), the liquidation preference payable equals the sum of (A) 550% of the Series A-1 stated value per share plus (B) an amount equal to (x) 550% of any accrued, but unpaid, preferred dividends (as defined in the Certificate of Designation) plus (y) any unpaid participating dividends (as defined in the Certificate of Designation). In the case of a deemed liquidation event (as defined in the Certificate of Designation), the multiplier is increased to 600%. The Series A-1 is convertible at any time at the option of the holder based on the then applicable conversion rate. If conversion is in connection with a liquidation, the holder is entitled to receive 550% of the number of shares of common stock issuable based upon the then applicable conversion rate. In the event of a deemed liquidation event, the multiplier is increased to 600%. Additionally, the holder may irrevocably require the Company to redeem the Series A-1 in the event of a deemed liquidation event for the sum of (A) 600% of the Series A-1 stated value per share plus (B) an amount equal to (x) 600% of any accrued, but unpaid, preferred dividends plus (y) any unpaid participating dividends, although such redemption may not be made without the consent of the senior secured noteholders if such notes are outstanding at the time of any such redemption. The shares of Series A-1 have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements of the Securities Act. The exchange of the Series A-1 for the shares of Series A held by the Investor was made in reliance on Sections 3(a)(9) and 4(a)(2) under the Securities Act, without general solicitation or advertising. Series B Convertible Preferred Stock Concurrent with completing the sale of Series A Convertible in October 2017, the Noteholders exchanged $1,500,000 in aggregate principal borrowings and $41,507 in accrued interest for 1,500,000 shares of Series B Convertible. The Series B Convertible were convertible into 2,112,675 shares of common stock. The exchange was accounted for as an extinguishment of debt, See Note 8. During May and June 2018, the Noteholders converted all 1,500,000 shares of Series B Convertible into 2,112,675 shares of common stock. Accordingly, there are no longer any shares of Series B Convertible issued and outstanding.

Stock-Based Compensation

12 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

12. Stock-Based Compensation

2011 Equity Incentive Plan

The Company’s 2011 Equity Compensation Plan (the “2011 Plan”) provided for the Company to sell or issue restricted common stock, restricted stock units (“RSUs”), performance-based awards, cash-based awards or to grant stock options for the purchase of common stock to officers, employees, consultants and directors of the Company. The 2011 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board. The number of shares of common stock reserved for issuance under the 2011 Plan is 1,159,420. As of September 30, 2018, performance-based stock unit awards (“PSUs”) representing 129,095 shares of the Company’s common stock were outstanding under the 2011 Plan. In light of the December 2015 adoption of the 2015 Equity Incentive Plan, no future awards under the 2011 Plan will be granted.

2015 Equity Incentive Plan

In December 2015, the Company adopted the 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards and other forms of equity compensation to Company employees, directors and consultants. As of September 30, 2018, the maximum number of shares of common stock that may be issued under the 2015 Plan is 8,404,023 shares and 5,558,678 shares remained available for grant under the 2015 Plan.

The Company recognizes the grant date fair value of each stock-based award over the vesting period of the award. The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the years ended September 30, 2018 and 2017:

	Year Ended Ended September 30,
	2018			2017
Research and development		$	19,450		$	1,001,022
General and administrative			1,966,420			7,570,408
		$	1,985,870		$	8,571,430

Stock options

The following table summarizes all of the Company’s stock option activity for the year ended September 30, 2018:

	Number of Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)
Balance at October 1, 2017		—		$	—
Granted		1,667,075			0.93
Expired/forfeited/cancelled		(209,930)			1.10
Balance at September 30, 2018		1,457,145			0.93		9.7
Vested and exercisable		30,000			1.32		0.1
Vested and expected to vest at September 30, 2018		1,457,145		$	0.90		9.7

As of September 30, 2018, the aggregate intrinsic value of the stock options was $131,442. The aggregate intrinsic value represents the total amount by which the fair value of the common stock subject to options exceeds the exercise price of the related options.

The Company estimated the fair value of each stock option award on the grant date using the Black-Scholes option pricing model, wherein expected volatility is based on historical volatility of the publicly traded common stock of a peer group of companies. The expected term calculation is based on the “simplified” method described in Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment, and SAB No. 110, Share-Based Payment, since the simplified method provides a reasonable estimate in comparison to actual experience. The risk-free interest rate is based on the U.S. Treasury yield at the date of grant for an instrument with a maturity that is commensurate with the expected term of the stock options. The dividend yield is zero since the Company has never paid cash dividends on its common stock, and has no present intention to pay cash dividends. Options granted under the 2015 Plan generally vest over two to four years and have a term of 10 years.

The weighted-average grant date fair value of the options awarded to employees for the year ended September 30, 2018 was $0.56 per share. The following table presents the weighted-average assumptions used in the option pricing model for stock options:

			Year Ended September 30, 2018
Risk-free interest rate			2.80%
Expected life			6.0 years
Expected volatility			71%
Expected dividend yield			—

As of September 30, 2018, there was $726,930 of unrecognized compensation expense that is expected to be recognized over a weighted-average period of 3.1 years.

Performance-Based stock units

The Company has issued PSUs, which generally have a ten year life from the date of grant and vest 50% after the third anniversary from issuance and the remaining 50% on the fourth anniversary. The PSUs are exercisable upon the earlier of (i) a change in control, (ii) consummation of an initial public offering, or (iii) a corporate valuation in excess of $400 million. Upon exercise, the PSU holder receives common stock or cash at the Company’s discretion.

The following table summarizes the activity related to PSUs during the years ended September 30, 2018 and 2017:

	Number of PSUs		Base Price Per PSU
Balance at October 1, 2016		247,309		$	6.33
Forfeitures		(71,779)			6.46
Balance at October 1, 2017		175,530			6.27
Forfeitures		(46,435)			6.43
Balance at September 30, 2018		129,095			6.25
Vested and exercisable		128,660			6.23
Vested and expected to vest at September 30, 2018		129,095		$	6.25

As of September 30, 2018, there was $1,552 of unamortized expense that will be recognized over a weighted-average period of 0.4 years.

Restricted stock units

The Company has granted RSUs that generally vest over a period of two to four years from the date of grant. The following table summarizes the activity related to RSUs during the years ended September 30, 2018 and 2017:

	Number of RSUs		Weighted Average Grant Date Fair Value
Balance at October 1, 2016		1,094,351		$	28.61
Granted		615,000			2.11
Vested and settled		(483,913)			29.05
Forfeitures		(285,559)			3.14
Balance at October 1, 2017		939,879			18.78
Granted		20,000			1.16
Vested and settled		(842,889)			18.40
Forfeitures		(55,881)			17.67
Balance at September 30, 2018		61,109		$	19.23

As of September 30, 2018, there was $544,691 of unamortized expense that will be recognized over a weighted-average period of 0.95 years.

Collaboration Arrangements	12 Months Ended
Collaboration Arrangements	Sep. 30, 2018
Collaboration Arrangements [Abstract]
Collaboration Arrangements	13. Collaboration Arrangements Huahai Agreement In May 2013, the Company entered into strategic license and collaboration arrangement with Zhejiang Huahai Pharmaceutical Co., Ltd (“Huahai”) under which the Company granted Huahai and its affiliates an exclusive license for the research, development, manufacture, use or sale of ONS-3010 or ONS-1045 in China, including, the People’s Republic of China, Hong Kong, Macau and Taiwan. In addition, the Company granted Huahai a right and license under the Selexis Technology agreement to establish a production process for the products in the agreed territory and to market the products in the agreed territory pursuant to the relevant terms and conditions of the Company’s commercial license agreement with Selexis. Under the terms of the arrangement, the Company has received $7,500,000 in upfront payments and non-substantive milestones and received $8,500,000 in substantive milestones. The Company determined that the deliverables under the Huahai arrangement were the exclusive license and the research and development services to be completed by the Company. Since the license did not have standalone value, the upfront and non-substantive milestones payments received have been deferred and are being recognized ratably on a straight line basis through December 2021, the expected date in which the research and development will be completed. Substantive milestones received under the Huahai arrangement are recognized upon achievement. During each of the years ended September 30, 2018 and 2017, the Company recognized $714,848 of deferred revenues. As of September 30, 2018 and 2017, deferred revenue included in the Company’s consolidated balance sheet related to the Huahai arrangement was $2,323,254 and $3,038,102, respectively. IPCA License and Collaboration Agreement In August 2013, the Company entered into a strategic license agreement with IPCA Laboratories Limited and its affiliates (“IPCA”) under which the Company granted IPCA a license for the research, development, manufacture, use or sale of the ONS-3010 and, by amendment in May 2014, the ONS-1045 biosimilar product candidates with respect to India, Sri-Lanka, and Myanmar, and non-exclusive with respect to Nepal and Bhutan, or collectively, the agreed territory. In addition, the Company granted IPCA a right and license under the Selexis Technology to enable IPCA to establish an exclusive production process for the products in its agreed territory and to exclusively market the products in the agreed territory. The Company also agreed not to amend or terminate its rights under its commercial license agreement with Selexis without IPCA’s prior written consent. Pursuant to the agreement, the Company agreed to continue the non-clinical and clinical development of each of ONS-3010 and ONS-1045 and corresponding products around the world and to develop and commercialize such products through Phase 3 clinical trials and regulatory approval in the United States and European Union. These obligations continue until termination of the agreement or the individual development programs or upon final regulatory approval of the last product for such biosimilars in the United States or European Union. The Company agreed to provide IPCA with a pre-IND package as submitted to EMEA and FDA, as well as perform preclinical development and characterization of ONS-3010 and ONS-1045 so as to enable IPCA to file an IND to conduct clinical trials and to perform clinical trials. Under the terms of the agreement, the Company has received upfront and non-substantive milestone payments of $2,400,000, and received $1,000,000 in regulatory milestone payments. In addition, the Company is eligible to receive royalties at a low double-digit percentage rate of annual net sales of products by IPCA and its affiliates in the agreed territory. For each of ONS-3010 and ONS-1045, IPCA agreed to fund a portion of the global costs associated with the Phase 3 clinical trials. The Company determined that the deliverables under the IPCA arrangement were the exclusive license and the research and development services to be completed by the Company. Since the license did not have standalone value, the upfront and non-substantive milestones payments received have been deferred and are being recognized ratably on a straight line basis through December 2019, the expected date in which the research and development will be completed. Substantive milestone payments received under the IPCA arrangement are recognized upon achievement. Cost reimbursements from IPCA related to the global costs associated with the Phase 3 clinical trials are recorded as a reduction in research and development expense. As of September 30, 2018, the Company has received an aggregate of $5.0 million of payments from IPCA under its various agreements. During each of the years ended September 30, 2018 and 2017, the Company recognized deferred revenues of $261,072. As of September 30, 2018 and 2017, deferred revenue included in the Company’s consolidated balance sheets was $848,486 and $1,109,558, respectively. Liomont Agreement In June 2014, the Company entered into a strategic license agreement with Liomont, under which the Company granted Liomont and its affiliates an exclusive, sublicenseable license in Mexico for the research, development, manufacture, use or sale of the ONS-3010 and ONS-1045 biosimilar product candidates in Mexico. In addition, the Company granted Liomont a non-exclusive right and license under the Selexis Technology and related intellectual property to enable Liomont to distribute, market and commercialize the products in Mexico. The Company also agreed not to amend or terminate its rights under the commercial agreement with Selexis without Liomont’s prior written consent. Under the terms of the agreement, the Company has received upfront payments and non-substantive milestone payments of $2,000,000 and received $1,000,000 in regulatory milestone payments. In addition, the Company is eligible to receive up to $2,000,000 in future substantive milestone payments. For each of ONS-3010 and ONS-1045, Liomont agreed to fund a portion of the global costs for Phase 3 clinical trials. The Company is eligible to receive tiered royalties at upper single-digit to low double-digit percentage rates of annual net sales of products by Liomont and its affiliates in Mexico. The Company determined that the deliverables under the Liomont arrangement were the exclusive license and the research and development services to be completed by the Company. Since the license did not have standalone value, the upfront payments received have been deferred and are being recognized ratably on a straight line basis through December 2019, the expected date in which the research and development will be completed. Cost reimbursements from Liomont related to the global costs associated with the Phase 3 clinical trials are recorded as a reduction in research and development expense. As of September 30, 2018, the Company has received an aggregate of $3.0 million of upfront and milestone payments from Liomont. During the years ended September 30, 2018 and 2017, the Company recognized deferred revenue of $236,641 for both periods, respectively. As of September 30, 2018 and 2017, deferred revenue included in the Company’s consolidated balance sheets was $769,083 and $1,005,724. BioLexis Agreement In July 2017, the Company entered into a strategic licensing agreement with BioLexis, under which it granted BioLexis and its affiliates a perpetual, irrevocable, exclusives sublicensable license in the agreed territory for the research, development, manufacture, use or sale of the ONS-1045 biosimilar product candidate in the agreed territory. The agreed territory includes all emerging markets, but specifically excludes major developed markets, such as the United States, Canada, Europe, Japan, Australia and New Zealand, and smaller markets where the Company has existing licensing arrangements, such as Mexico, greater China and India. The Company received an initial upfront payment from BioLexis of $1.25 million, and an additional $1.25 million upon meeting a notice and acknowledgment milestone. In September 2017 the Company and BioLexis superseded and replaced the strategic license agreement with a Joint Development and License Agreement (the “JDLA”) providing for the development and commercialization of the Company’s ONS-3010 and ONS-1045 biosimilar product candidates in the same geographic territories. In exchange for granting BioLexis a perpetual, irrevocable, exclusive, sublicensable license in the agreed territory for the research, development, manufacture, use or sale of the ONS-3010 and ONS-1045 biosimilar product candidates in the agreed territory, BioLexis made an additional payment of $2.5 million in connection with the JDLA. The Company may receive up to an additional $2.5 million milestone payments under the JDLA for each licensed product upon achievement of certain net profit thresholds. The parties agreed to share net profits based on sales of licensed products in the agreed territory, in proportions weighed in BioLexis’ favor, subject to adjustment as provided in the agreement. During the years ended September 30, 2018 and 2017, the Company recognized revenue of $1,874,999 and $2,598,958, respectively, under the BioLexis agreements. As of September 30, 2018 and 2017, deferred revenue included in the Company’s consolidated balance sheet was $526,042 and $2,401,042, respectively.

Related-Party Transactions	12 Months Ended
Related-Party Transactions	Sep. 30, 2018
Related Party Transactions [Abstract]
Related-Party Transactions	14. Related-Party Transactions In May 2018, the Company negotiated a contract with Sonnet Biotherapeutics, Inc. (“Sonnet”) to provide contract development and manufacturing (“CDMO”) services. The maximum contract value is estimated to be approximately $5.1 million, if all milestones are met. Additionally, in order to provide services to Sonnet and other potential CDMO customers, in November 2017, the Company acquired laboratory and office equipment from Sonnet with a value of $115,000 and during the year ended September 30, 2018, assumed leases of $201,000 for equipment necessary for the planned expansion of the Company’s development and manufacturing facilities. Such leases were personally guaranteed by Pankaj Mohan, Ph.D., the Company’s former chairman and chief executive officer, and current Class III director. Dr. Mohan and Mr. Donald Griffith, Class II Director, are members of the board of directors of Sonnet, with Dr. Mohan serving as executive chairman of Sonnet. In addition, Dr. Mohan is a significant stockholder of Sonnet and Mr. Griffith is the president, chief executive officer and chief financial officer, of Sonnet. For other related party transactions during the year ended September 30, 2018 and 2017, refer to the Stockholder Notes (Note 7), Debt (Note 8) and the BioLexis Agreement (Note 13).

Income Taxes

12 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

15. Income Taxes

Income tax (benefit) expense for the years ended September 30, 2018 and 2017 consists of the following:

	Year Ended September 30,
	2018			2017
State tax		$	(3,148,216)		$	1,500
Foreign tax			(500,000)			500,000
		$	(3,648,216)		$	501,500

During the year ended September 30, 2018, the Company sold New Jersey NOLs in the amount of $38,470,278 resulting in the recognition of income tax benefits of $3,150,716.

A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:

	Year Ended September 30,
	2018		2017
U.S. federal statutory rate		(24.3)%		(34.0)%
State taxes, net of federal benefit		(6.9)		(6.4)
Sale of New Jersey net operating losses		(7.1)		—
Net operating loss		8.0		—
Change in tax rates		66.6		—
Foreign witholding tax		(1.5)		1.3
Permanent differences		(0.6)		(2.8)
Foreign tax credits		1.5		(1.6)
Research and development credit		(22.9)		—
Change in valuation allowance		(23.7)		44.8
Other		0.1		—
Effective income tax rate		(10.8)%		1.3%

The tax effects of the temporary differences that gave rise to deferred taxes were as follows:

	September 30,
	2018			2017
Deferred tax assets:
Net operating loss carryforwards		$	39,532,689		$	48,828,141
Stock-based compensation			10,227,514			14,098,985
Deferred revenue			1,264,069			3,017,238
Research and development credit carryforward			8,491,452			757,701
Foreign tax credits			2,357,309			2,857,309
Accruals and others			605,173			1,539,943
Gross deferred tax assets			62,478,206			71,099,317
Less: valuation allowance			(61,893,959)			(69,902,446)
			584,247			1,196,871
Deferred tax liability:
Fixed assets			(584,247)			(1,196,871)
Net deferred tax assets		$	—		$	—

As of September 30, 2018, the Company has approximately $164.7 million and $68.1 million of federal and New Jersey NOLs that will begin to expire in 2030 and 2036, respectively. As of September 30, 2018, the Company has approximately $0.4 million of foreign net operating losses with no expiration. As of September 30, 2018, the Company has federal and state research and development tax credit carryforwards of $6.6 million and $1.9 million available, respectively, to reduce future tax liabilities which will begin to expire in 2032 and 2023 respectively. As of September 30, 2018, the Company has Federal foreign tax credit carryforwards of $2.4 million available to reduce future tax liabilities that will begin to expire starting in 2023, which is included in the balance of unrecognized tax benefits. Realization of the deferred tax asset is contingent on future taxable income and based upon the level of historical losses, management has concluded that the deferred tax asset does not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance continues to be recorded against the Company’s deferred tax assets as of September 30, 2018 and 2017. The valuation allowance decreased $8.0 million during the year ended September 30, 2018 and increased $17.2 million during the year ended September 30, 2017.

When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely-than-not be realized. The determination as to whether the tax benefit will more-likely-than-not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes interest and penalties accrued on any unrecognized tax benefits within the provision for income taxes in its consolidated statements of operations.

The 2017 Tax Cuts and Jobs Act, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from 34% to 21%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. For the fiscal year ending September 30, 2018, the federal tax rate is 24.3%. The 2017 Tax Cuts and Jobs Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of the Company’s foreign subsidiaries to U.S. taxation as global intangible low-taxed income. These changes are effective beginning in 2018. In regard to the change in the federal tax rate as it relates to the Company’s deferred tax assets and liabilities, the Company has decreased its related deferred tax assets by $22.4 million along with a corresponding offset against the valuation allowance for these deferred tax assets.

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

	Year Ended September 30,
	2018			2017
Balance at beginning of year		$	2,352,129		$	1,854,629
Changes based on tax positions related to the current year			(496,000)			497,500
Balance at end of year		$	1,856,129		$	2,352,129

The Company does not anticipate material change in the unrecognized tax benefits in the next 12 months. These unrecognized tax benefits, if recognized, would affect the annual effective tax rate. The Company’s income tax returns for the years from 2011 through 2017 remain open for examination by the Internal Revenue Service as well as various states and municipalities.

Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company’s net operating loss carryforwards may be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carryforwards. The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and therefore no determination has been made whether the net operating loss carryforward is subject to any Internal Revenue Code Section 382 limitation. To the extent there is a limitation, there would be a reduction in the deferred tax assets with an offsetting reduction in the valuation allowance.

Basis of Presentation and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Basis of presentation

Use of estimates

Fair value of financial instruments

Property and equipment

Property and equipment are recorded at cost. Depreciation and amortization is determined using the straight-line method over the estimated useful lives ranging from 3 to 10 years. Leasehold improvements are amortized over the life of the lease or the estimated useful life of the assets, whichever is shorter. Expenditures for maintenance and repairs are expensed as incurred while renewals and betterments are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in operations.

Long-lived assets

Stock-based compensation

Revenue recognition

Incentive and tax receivables

Research and development

Income taxes

Net loss per share

Basic net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period.

The following table sets forth the computation of basic earnings per share and diluted earnings per share:

	Year Ended September 30,
	2018			2017
Basic Earnings Per Share
Net loss attributable to common stockholders		$	(48,018,854)		$	(40,025,870)
Common stock outstanding (weighted average)			39,457,664			24,022,371
Basic net loss per share		$	(1.22)		$	(1.67)
Diluted Earnings Per Share
Net loss attributable to common stockholders		$	(48,018,854)		$	(40,025,870)
Add change in fair value of warrant liability			—			(3,158,469)
Diluted net loss			(48,018,854)			(43,184,339)
Common stock outstanding (weighted average)			39,457,664			24,022,371
Add shares from dilutive warrants			—			19,418
Common stock equivalents			39,457,664			24,041,789
Diluted net loss per share		$	(1.22)		$	(1.80)

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September 30, 2018 and 2017, as they would be antidilutive:

	As of September 30,
	2018		2017
Series A-1 convertible preferred stock		9,101,717		—
Performance-based stock units		129,095		175,530
Restricted stock units		61,109		939,879
Stock options		1,557,145		—
Common stock warrants		45,292,532		7,484,504

Recently issued accounting pronouncements

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Schedule of computation of basic earnings per share and diluted earnings per share

	Year Ended September 30,
	2018			2017
Basic Earnings Per Share
Net loss attributable to common stockholders		$	(48,018,854)		$	(40,025,870)
Common stock outstanding (weighted average)			39,457,664			24,022,371
Basic net loss per share		$	(1.22)		$	(1.67)
Diluted Earnings Per Share
Net loss attributable to common stockholders		$	(48,018,854)		$	(40,025,870)
Add change in fair value of warrant liability			—			(3,158,469)
Diluted net loss			(48,018,854)			(43,184,339)
Common stock outstanding (weighted average)			39,457,664			24,022,371
Add shares from dilutive warrants			—			19,418
Common stock equivalents			39,457,664			24,041,789
Diluted net loss per share		$	(1.22)		$	(1.80)

Schedule of dilutive securities excluded from the computation weighted-average shares

	As of September 30,
	2018		2017
Series A-1 convertible preferred stock		9,101,717		—
Performance-based stock units		129,095		175,530
Restricted stock units		61,109		939,879
Stock options		1,557,145		—
Common stock warrants		45,292,532		7,484,504

Fair Value Measurements (Tables)

12 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Schedule of assets and liabilities measured at fair value on a recurring basis

	September 30, 2018
	(Level 1)			(Level 2)			(Level 3)
Liabilities
Warrant liability		$	—		$	—		$	1,227,225

	September 30, 2017
	(Level 1)			(Level 2)			(Level 3)
Liabilities
Warrant liability		$	—		$	—		$	2,274,954

Summary of changes in the fair value of the Company's Level 3 valuation for the warrant liability

Balance at October 1, 2016	$	—
Issuance of warrants		5,493,619
Exercise of warrants		(60,196)
Change in fair value		(3,158,469)
Balance at September 30, 2017		2,274,954
Change in fair value		(1,047,729)
Balance at September 30, 2018	$	1,227,225

Schedule of fair value of the warrant liability estimated using Black-Scholes option pricing model

	September 30,
	2018	2017
Risk-free interest rate	2.90%	1.77%
Remaining contractual life of warrant	3.39 years	4.67 years
Expected volatility	82%	82%
Annual dividend yield	0%	0%
Fair value of common stock	$0.98 per share	$1.37 per share

Property and Equipment (Tables)

12 Months Ended

Sep. 30, 2018

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	September 30,
	2018			2017
Laboratory equipment		$	14,333,624		$	11,574,473
Leasehold improvements			10,095,100			10,032,640
Computer software and hardware			483,807			472,054
Land and building			3,000,000			—
Construction in progress			2,276,737			2,654,675
			30,189,268			24,733,842
Less: accumulated depreciation and amortization			(11,699,292)			(8,644,940)
		$	18,489,976		$	16,088,902

Schedule of future minimum lease payments under capital leases

2019	$	1,947,199
2020		1,594,917
2021		1,493,442
2022		1,522,660
2023		1,550,878
Thereafter		7,280,400
		15,389,496
Less: amounts representing interest		(11,415,446)
Less: current portion		(520,794)
Capital lease obligations, excluding current portion	$	3,453,256

Debt (Tables)

12 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Schedule of Senior Secured Notes debt

	September 30,
	2018			2017
Senior secured notes		$	13,500,000		$	15,000,000
Unamortized debt discount			(320,551)			(1,768,300)
		$	13,179,449		$	13,231,700

Schedule of debt

	September 30,
	2018			2017
Equipment loans		$	164,967		$	203,710
Less: current portion			(66,480)			(52,600)
Long-term debt		$	98,487		$	151,110

Schedule of future maturities of other indebtedness

2019	$	66,480
2020		48,204
2021		50,283
	$	164,967

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Stockholders' Equity (Deficit) (Tables)

12 Months Ended

Sep. 30, 2018

Stockholders' Equity Note [Abstract]

Schedule of warrants outstanding

Outstanding	Exercise Price Per Share			Expiration Date
3,333,333		$	6.60	February 18, 2019(i)
814,378		$	0.01	November 11, 2019
3,882,001		$	3.00	December 22, 2021(ii)
16,750,000		$	0.90	October 31, 2025
10,256,410		$	0.975	May 10, 2026
10,256,410		$	0.975	June 8, 2026
45,292,532

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Stock-Based Compensation (Tables)

12 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of stock-based compensation expense

	Year Ended Ended September 30,
	2018			2017
Research and development		$	19,450		$	1,001,022
General and administrative			1,966,420			7,570,408
		$	1,985,870		$	8,571,430

Schedule of stock option activity

	Number of Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)
Balance at October 1, 2017		—		$	—
Granted		1,667,075			0.93
Expired/forfeited/cancelled		(209,930)			1.10
Balance at September 30, 2018		1,457,145			0.93		9.7
Vested and exercisable		30,000			1.32		0.1
Vested and expected to vest at September 30, 2018		1,457,145		$	0.90		9.7

Schedule of weighted-average assumptions used in option pricing model for stock options

			Year Ended September 30, 2018
Risk-free interest rate			2.80%
Expected life			6.0 years
Expected volatility			71%
Expected dividend yield			—

Schedule of performance-based stock units activity

	Number of PSUs		Base Price Per PSU
Balance at October 1, 2016		247,309		$	6.33
Forfeitures		(71,779)			6.46
Balance at October 1, 2017		175,530			6.27
Forfeitures		(46,435)			6.43
Balance at September 30, 2018		129,095			6.25
Vested and exercisable		128,660			6.23
Vested and expected to vest at September 30, 2018		129,095		$	6.25

Schedule of restricted stock units activity

	Number of RSUs		Weighted Average Grant Date Fair Value
Balance at October 1, 2016		1,094,351		$	28.61
Granted		615,000			2.11
Vested and settled		(483,913)			29.05
Forfeitures		(285,559)			3.14
Balance at October 1, 2017		939,879			18.78
Granted		20,000			1.16
Vested and settled		(842,889)			18.40
Forfeitures		(55,881)			17.67
Balance at September 30, 2018		61,109		$	19.23

Income Taxes (Tables)

12 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Schedule of Income tax expense

	Year Ended September 30,
	2018			2017
State tax		$	(3,148,216)		$	1,500
Foreign tax			(500,000)			500,000
		$	(3,648,216)		$	501,500

Schedule of reconciliation of income tax expense (benefit) at the statutory federal income tax rate

	Year Ended September 30,
	2018		2017
U.S. federal statutory rate		(24.3)%		(34.0)%
State taxes, net of federal benefit		(6.9)		(6.4)
Sale of New Jersey net operating losses		(7.1)		—
Net operating loss		8.0		—
Change in tax rates		66.6		—
Foreign witholding tax		(1.5)		1.3
Permanent differences		(0.6)		(2.8)
Foreign tax credits		1.5		(1.6)
Research and development credit		(22.9)		—
Change in valuation allowance		(23.7)		44.8
Other		0.1		—
Effective income tax rate		(10.8)%		1.3%

Schedule of deferred taxes

	September 30,
	2018				2017
Deferred tax assets:
Net operating loss carryforwards		$	39,532,689			$	48,828,141
Stock-based compensation			10,227,514				14,098,985
Deferred revenue			1,264,069				3,017,238
Research and development credit carryforward			8,491,452				757,701
Foreign tax credits			2,357,309				2,857,309
Accruals and others			605,173				1,539,943
Gross deferred tax assets			62,478,206				71,099,317
Less: valuation allowance			(61,893,959	)			(69,902,446)
			584,247				1,196,871
Deferred tax liability:
Fixed assets			(584,247)				(1,196,871)
Net deferred tax assets		$	—			$	—

Schedule of reconciliation of unrecognized tax benefits

	Year Ended September 30,
	2018			2017
Balance at beginning of year		$	2,352,129		$	1,854,629
Changes based on tax positions related to the current year			(496,000)			497,500
Balance at end of year		$	1,856,129		$	2,352,129

Liquidity (Detail Textuals)			1 Months Ended		2 Months Ended	12 Months Ended
Liquidity (Detail Textuals)	Nov. 07, 2018 USD ($) $ / shares	Nov. 05, 2018 USD ($) Tranches $ / shares shares	Nov. 30, 2018 USD ($)	May 31, 2018 shares	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)
Liquidity [Line Items]
Accumulated deficit						$ (216,307,363)	$ (186,215,402)
Aggregate indebtedness						13,500,000
Notes payable to stockholders						4,612,500	$ 4,612,500
Notes payable to stockholders on due demand						1,000,000
Notes payable to stockholders on matures						3,600,000
Proceeds from issuance of private placement						$ 20,000,000
Subsequent Event
Liquidity [Line Items]
Sale of unused net operating losses and research and development tax credits			$ 3,700,000
Proceeds from sale of net operating losses and research and development tax credits			$ 3,400,000
Private Placement \| Purchase agreement
Liquidity [Line Items]
Number of common stock for private placement \| shares				12,754,766
Private Placement \| Purchase agreement \| BioLexis \| Subsequent Event
Liquidity [Line Items]
Amount of common stock for private placement		$ 20,000,000
Common stock for private placement, per share \| $ / shares		$ 0.9327
Number of common stock for private placement \| shares		12,865,872
Number of tranches \| Tranches		2
Proceeds from common stock for aggregate cash					$ 12,000,000
Initial payment of raising additional capital	$ 2,200,000
Reduced the exercise price of the warrants \| $ / shares		$ 1.50
Extended expiration tear of warrants		3 years
Private Placement \| Purchase agreement \| BioLexis \| Subsequent Event \| January 3, 2019 and February 1, 2019
Liquidity [Line Items]
Remaining common stock for aggregate cash		$ 8,000,000
Private Placement \| Purchase agreement \| BioLexis \| Subsequent Event \| Senior secured notes convertible
Liquidity [Line Items]
Common stock at a price, per share \| $ / shares	$ 1.11924
Percentages of price per share paid	120.00%

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Basic Earnings Per Share
Net loss attributable to common stockholders	$ (48,018,854)	$ (40,025,870)
Common stock outstanding (weighted average) (in shares)	39,457,664	24,022,371
Basic net loss per share	$ (1.22)	$ (1.67)
Diluted Earnings Per Share
Net loss attributable to common stockholders	$ (48,018,854)	$ (40,025,870)
Add change in fair value of warrant liability		(3,158,469)
Diluted net loss	$ (48,018,854)	$ (43,184,339)
Common stock outstanding (weighted average) (in shares)	39,457,664	24,022,371
Add shares from dilutive warrants	0	19,418
Common stock equivalents	39,457,664	24,041,789
Diluted net loss per share (in dollars per share)	$ (1.22)	$ (1.80)

Basis of Presentation and Summary of Significant Accounting Policies (Details 1) - shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Series A-1 convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	9,101,717	0
Performance-based stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	129,095	175,530
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	61,109	939,879
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,557,145	0
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	45,292,532	7,484,504

Basis of Presentation and Summary of Significant Accounting Policies (Detail Textuals) $ in Millions, $ in Millions	12 Months Ended
	Sep. 30, 2018 USD ($)	Sep. 30, 2018 AUD ($)
Accounting Policies [Abstract]
Estimated useful lives	3 to 10 years	3 to 10 years
Methods of depreciation and amortization	straight-line method	straight-line method
Annual aggregate revenues		$ 20.0
Estimate of the amount of cash refund eligible spending as part of this incentive program	$ 0.3
Refundable GST on expenses	0.1
Operations related to cash refund	0.3
Adjustment to increase to accumulated deficit	$ 3.6

Fair Value Measurements (Details 1) - USD ($)	12 Months Ended
Fair Value Measurements (Details 1) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	$ 2,274,954	$ 0
Issuance of warrants		5,493,619
Exercise of warrants		(60,196)
Change in fair value	(1,047,729)	(3,158,469)
Balance	$ 1,227,225	$ 2,274,954

Fair Value Measurements (Details 2)	Sep. 30, 2018 $ / shares	Sep. 30, 2017 $ / shares
Risk-free interest rate
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	2.90	1.77
Remaining contractual life of warrant
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term	3 years 4 months 21 days	4 years 8 months 1 day
Expected volatility
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	82	82
Annual dividend yield
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0
Fair value of common stock
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value	$ 0.98	$ 1.37

Property and Equipment (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 30,189,268	$ 24,733,842
Less: accumulated depreciation and amortization	(11,699,292)	(8,644,940)
Property and equipment, net	18,489,976	16,088,902
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	14,333,624	11,574,473
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	10,095,100	10,032,640
Computer software and hardware
Property, Plant and Equipment [Line Items]
Property and equipment, gross	483,807	472,054
Land and building
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,000,000	0
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,276,737	$ 2,654,675

Property and Equipment (Details 1) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Less: current portion	$ (520,794)	$ (341,120)
Capital lease obligations, excluding current portion	3,453,256	$ 28,067
Laboratory Equipment
Property, Plant and Equipment [Line Items]
2019	1,947,199
2020	1,594,917
2021	1,493,442
2022	1,522,660
2023	1,550,878
Thereafter	7,280,400
Total future minimum lease payments under capital leases	15,389,496
Less: amounts representing interest	(11,415,446)
Less: current portion	(520,794)
Capital lease obligations, excluding current portion	$ 3,453,256

Property and Equipment (Detail Textuals) - USD ($)	1 Months Ended	12 Months Ended
Property and Equipment (Detail Textuals) - USD ($)	Feb. 28, 2018	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense		$ 3,054,352	$ 2,692,100
Corporate office, interest rate		43.90%
Laboratory Equipment
Property, Plant and Equipment [Line Items]
Laboratory equipment under capital leases		$ 7,953,856	3,692,913
Accumulated depreciation related to leased equipment		$ 1,619,741	$ 1,061,901
Percentages lease occupying corporate facility	100.00%
Term of two renewal options	5 years
Lease obligation and corresponding building asset of estimated fair value	$ 3,000,000
Laboratory Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Term of capital leases		12 months
Capital leases interest rate		4.00%
Laboratory Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Term of capital leases		36 months
Capital leases interest rate		19.40%

Accrued Expenses (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Accrued Liabilities, Current [Abstract]
Compensation	$ 2,231,122	$ 3,688,592
Severance and related costs	396,138	0
Lease termination obligation	395,071	0
Research and development	1,065,169	1,637,657
Interest payable	1,991,044	1,047,122
Professional fees	313,585	521,973
Director fees	59,122	376,695
Other accrued expenses	7,220	65,430
Accrued expenses	$ 6,458,471	$ 7,337,469

Stockholder Notes (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Debt Instrument [Line Items]
Stockholder notes	$ 4,612,500	$ 4,612,500
Less: current portion	(4,612,500)	(4,612,500)
Long-tem stockholder notes	0	0
Restricted stock purchase notes
Debt Instrument [Line Items]
Stockholder notes	800,000	800,000
Common stock repurchase note
Debt Instrument [Line Items]
Stockholder notes	2,812,500	2,812,500
Working capital notes
Debt Instrument [Line Items]
Stockholder notes	$ 1,000,000	$ 1,000,000

Stockholder Notes (Detail Textuals) - USD ($)	12 Months Ended
Stockholder Notes (Detail Textuals) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Debt Instrument [Line Items]
Interest expense related to the stockholder notes	$ 300,000	$ 320,000
Stockholder notes	4,612,500	4,612,500
Notes payable to stockholders on due demand	1,000,000
Notes payable to stockholders on matures	3,600,000
Restricted stock repurchase notes
Debt Instrument [Line Items]
Stockholder notes	$ 800,000	800,000
Restricted stock repurchase notes \| Minimum
Debt Instrument [Line Items]
Interest rate	0.00%
Restricted stock repurchase notes \| Maximum
Debt Instrument [Line Items]
Interest rate	4.00%
Common stock repurchase note
Debt Instrument [Line Items]
Stockholder notes	$ 2,812,500	2,812,500
Working capital notes
Debt Instrument [Line Items]
Stockholder notes	1,000,000	$ 1,000,000
Working capital notes \| Stockholder and former chief executive officer
Debt Instrument [Line Items]
Note collateralized by common shares	$ 300,000
Working capital notes \| Minimum
Debt Instrument [Line Items]
Interest rate	0.00%
Working capital notes \| Maximum
Debt Instrument [Line Items]
Interest rate	30.00%

Debt (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Debt Instrument [Line Items]
Senior secured notes	$ 13,179,449
Senior Secured Notes
Debt Instrument [Line Items]
Senior secured notes	13,500,000	$ 15,000,000
Unamortized debt discount	(320,551)	(1,768,300)
Senior secured notes	$ 13,179,449	$ 13,231,700

Debt (Details 1) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Debt Disclosure [Abstract]
Equipment loans	$ 164,967	$ 203,710
Less: current portion	(66,480)	(52,600)
Long-term debt	$ 98,487	$ 151,110

Debt (Details 2)	Sep. 30, 2018 USD ($)
Debt Disclosure [Abstract]
2019	$ 66,480
2020	48,204
2021	50,283
Total debt	$ 164,967

Debt (Detail Textuals) - USD ($)			1 Months Ended						2 Months Ended	3 Months Ended	12 Months Ended
Debt (Detail Textuals) - USD ($)	Nov. 05, 2018	Jan. 31, 2017	Dec. 31, 2018	Nov. 30, 2018	Jun. 30, 2018	Oct. 31, 2017	Apr. 30, 2017	Dec. 31, 2016	May 31, 2017	Dec. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	May 31, 2018
Debt Instrument [Line Items]
Interest expense											$ 1,997,231	$ 4,441,886
Warrants exercise price per share											$ 1.50
Aggregate principal amount of notes and warrants issued		$ 1,650,000
Repayment of senior secured bank loans											$ 127,736	2,677,771
Stock issued during period for conversion of convertible securities											14,359,816
Loss on extinguishment of debt											$ (1,252,353)
Conversion rate per share											$ 1.11924
Expiration period of warrant extended											3 years
Subsequent event
Debt Instrument [Line Items]
Additional capital raising commitments			$ 1,170,000	$ 2,200,000
Series B Convertible Preferred Stock
Debt Instrument [Line Items]
Stock issued during period for conversion of convertible securities						$ 1,500,000
Stock issued during period for conversion of convertible securities (in shares)						1,500,000
Accrued interest						$ 41,507
Conversion of Series B convertible preferred stock into common stock (in shares)											(1,500,000)
Purchase agreement
Debt Instrument [Line Items]
Warrants exercise price per share													$ 0.975
Purchase agreement \| Private Placement \| BioLexis \| Subsequent event
Debt Instrument [Line Items]
Amount of common stock for private placement	$ 20,000,000
Bridge note
Debt Instrument [Line Items]
Unsecured bridge notes								$ 1,850,000		$ 1,850,000
Interest rate								15.00%		15.00%
Debt Instrument, term										1 year
Equipment loan
Debt Instrument [Line Items]
Debt instrument, description of collateral											collateralized by the related equipment purchased and an unconditional personal guarantee by the founding stockholder and former chief executive officer.
Interest expense											$ 27,660	35,608
Equipment loan \| Minimum
Debt Instrument [Line Items]
Debt, interest rate											12.00%
Debt Instrument, term											1 year
Equipment loan \| Maximum
Debt Instrument [Line Items]
Debt, interest rate											16.00%
Debt Instrument, term											5 years
Senior Secured Notes
Debt Instrument [Line Items]
Warrants to acquire common stock									1,304,500
Aggregate principal amount of notes and warrants issued									$ 5,000,000
Initial fair value of warrant liability									1,400,000
Debt issuance costs									$ 3,635
Senior Secured Notes \| Note and Warrant Purchase Agreement (the "NWPA")
Debt Instrument [Line Items]
Interest rate								5.00%		5.00%
Debt instrument, maturity date								Dec. 22, 2017
Warrants to acquire common stock								2,300,000		2,300,000
Warrants exercise price per share								$ 3.00		$ 3.00
Term of warrants								5 years
Aggregate principal amount of notes and warrants issued								$ 8,350,000
Maximum number of shares called by warrants								1,920,500
Proceeds from issuance of secured debt								$ 6,500,000
Initial fair value of warrant liability								3,300,000		$ 3,300,000
Debt issuance costs								40,000		40,000
Senior Secured Notes \| Exchange Agreement \| Two existing investors \| Series B Convertible Preferred Stock
Debt Instrument [Line Items]
Stock issued during period for conversion of convertible securities												$ 1,500,000
Stock issued during period for conversion of convertible securities (in shares)												1,500,000
Accrued interest						$ 41,507
Loss on extinguishment of debt												$ 1,252,353
Conversion of Series B convertible preferred stock into common stock (in shares)					2,112,675
Senior Secured Notes \| Maximum \| Note and Warrant Purchase Agreement (the "NWPA")
Debt Instrument [Line Items]
Interest rate							5.00%
Senior secured promissory note							$ 15,000,000	$ 10,000,000		$ 10,000,000
Maximum number of shares called by warrants							1,665,000

Commitments (Details)	12 Months Ended
Commitments (Details)	Sep. 30, 2018 USD ($)
Lease Termination Obligation [Roll Forward]
Lease termination payments Balance October 1, 2017	$ 0
Lease termination payments expensed accrued expense	4,187,696
Cash payments of lease termination	(337,615)
Non cash items of lease termination	0
Lease termination payments Balance September 30, 2018	3,850,081
Derecognition of assets and liabilities Balance October 1, 2017	0
Derecognition of assets and liabilities expensed accrued expense	(14,014)
Cash payments of derecognition of assets and liabilities	0
Non cash items of derecognition of assets and liabilities	14,014
Derecognition of assets and liabilities	0
Balance October 1, 2017	0
Expensed accrued expense	4,173,682
Cash payments	(337,615)
Non cash items	14,014
Balance September 30, 2018	$ 3,850,081

Commitments (Details 1)	Sep. 30, 2018 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 180,000
2020	187,500
2021	195,000
Future minimum payments under noncancelable operating leases	$ 562,500

Commitments (Detail Textuals)	1 Months Ended				12 Months Ended
Commitments (Detail Textuals)	Aug. 31, 2018 USD ($)	Mar. 31, 2018 USD ($)	Feb. 28, 2018 USD ($)	Aug. 31, 2015 ft²	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)
Long-term Purchase Commitment [Line Items]
Rent expense under operating lease					$ 390,793	$ 421,028
Rent expense under the leases					$ 854,487	1,352,708
Defined contribution plan, maximum annual contributions per employee, percent					100.00%
Defined contribution plan, employer matching contribution, percent of match					100.00%
Description of defined contribution plan					The Company matches 100% of the first 3% of employee contributions
Expense related to matching contribution					$ 175,693	$ 209,782
Consideration for termination of lease	$ 5,800,000
Amount of execution of termination agreement	287,615
Payment for lease per month	$ 50,000
Terms of payment for lease	30 months
Lease payment in any event	$ 4,000,000
Date of payment event before	Feb. 01, 2021
Security deposit	$ 174,250
Final payment of lease obligation	$ 4,000,000
Loss on lease termination					(4,173,682)
Derecognized assets and liabilities associated with financing lease					4,200,000
Accrued expenses
Long-term Purchase Commitment [Line Items]
Lease termination obligation, current					395,071
Other liabilities
Long-term Purchase Commitment [Line Items]
Lease termination obligation, non-current					3,455,010
Office and laboratory space
Long-term Purchase Commitment [Line Items]
Description of lessee leasing arrangements, operating leases				Expires in March 2026
Net rentable area \| ft²				82,000
Technology license agreement
Long-term Purchase Commitment [Line Items]
Milestone payments amount					353,600
Strategic partnership agreement \| MTTR, LLC
Long-term Purchase Commitment [Line Items]
Milestone payments amount		$ 268,553
Monthly consulting fee			$ 58,333
Increase monthly fee Beginning February 2019			105,208
Aggregate amount of monthly consulting fees, expense reimbursement paid					602,629
Payment For Initial Upfront Payment					$ 75,000
Strategic partnership agreement \| MTTR, LLC \| United States
Long-term Purchase Commitment [Line Items]
Increase monthly fee Beginning February 2019			$ 170,833

Stockholders' Equity (Deficit) (Details)

12 Months Ended

Sep. 30, 2018

$ / shares

Class of Warrant or Right [Line Items]

Outstanding | shares

45,292,532

Exercise price per share | $ / shares

$ 1.50

Series A warrants

Class of Warrant or Right [Line Items]

Outstanding | shares

3,333,333

Exercise price per share | $ / shares

$ 6.6

Expiration date

Feb. 18, 2019

^[1]

Common stock warrants with expiration date of November 11, 2019

Class of Warrant or Right [Line Items]

Outstanding | shares

814,378

Exercise price per share | $ / shares

$ 0.01

Expiration date

Nov. 11, 2019

Senior Note Warrants

Class of Warrant or Right [Line Items]

Outstanding | shares

3,882,001

Exercise price per share | $ / shares

$ 3

Expiration date

Dec. 22, 2021

^[2]

Common stock warrants with expiration date of October 31, 2025

Class of Warrant or Right [Line Items]

Outstanding | shares

16,750,000

Exercise price per share | $ / shares

$ 0.9

Expiration date

Oct. 31, 2025

Common stock warrants with expiration date of May 10, 2026

Class of Warrant or Right [Line Items]

Outstanding | shares

10,256,410

Exercise price per share | $ / shares

$ 0.975

Expiration date

May 10, 2026

Common stock warrants issued with expiration date of June 8, 2026

Class of Warrant or Right [Line Items]

Outstanding | shares

10,256,410

Exercise price per share | $ / shares

$ 0.975

Expiration date

Jun. 08, 2026

[1]	In connection with the November 2018 purchase agreement with BioLexis providing for the private placement of $20.0 million of shares of the Company's common stock, the Company undertook to take such action as necessary to reduce the exercise price of the Series A warrants to $1.50 and extend the expiration date of such Series A warrants by three years.
[2]	In November 2018, the Company reduced the exercise price of the Senior Note Warrants to $1.50 and extended the expiration of the Senior Note warrants by three years. Such Senior Note Warrants now expire eight years from their initial issuance date.

Stockholders' Equity (Deficit) (Detail Textuals) - USD ($)		12 Months Ended
	Mar. 08, 2017	Sep. 30, 2017
Stockholders' Equity (Deficit) [Line Items]
Value of shares issued in cash		$ 1,503,127
Lincoln Park Capital, LLC
Stockholders' Equity (Deficit) [Line Items]
Value of common stock shares authorized to purchase	$ 15,400,000
Shares issued during period		737,817
Additional value of shares obligated to issue	$ 15,000,000
Closing price	$ 1.50
Number of shares purchase by sole discretion on any business day	30,000
Description of transaction	The price per share for such purchases will be equal to the lower of: (i) the lowest sale price on the applicable purchase date and (ii) the arithmetic average of the three (3) lowest closing sale prices for the Company’s common stock during the ten (10) consecutive business days ending on the business day immediately preceding such purchase date (in each case, to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction that occurs on or after the date of the purchase agreement).
Maximum amount of shares purchase increased as increase in share price	$ 1,000,000
Beneficial ownership percentage	4.99%
Value of shares issued in cash		$ 1,620,931
Payment for stock issuance cost		$ 147,540
Additional shares of common stock issued		122,418
Lincoln Park Capital, LLC \| Purchase agreement
Stockholders' Equity (Deficit) [Line Items]
Shares issued during period	113,205
Sale of Series A convertible preferred, net of costs (in shares)	113,206

Stockholders' Equity (Deficit) (Detail Textuals 1) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	May 31, 2018	Sep. 30, 2018	Sep. 30, 2017
Stockholders Equity [Line Items]
Warrants exercise price per share		$ 1.50
Purchase agreement
Stockholders Equity [Line Items]
Proceeds from issuance of warrants	$ 15.0
Term of warrant	8 years
Warrants exercise price per share	$ 0.975
Common stock warrants \| Purchase agreement
Stockholders Equity [Line Items]
Number of warrants purchase to issued common stock	20,512,820
Private Placement \| Purchase agreement
Stockholders Equity [Line Items]
Number of common stock for private placement	12,754,766
Common stock
Stockholders Equity [Line Items]
Number of common stock issued upon vesting of RSUs		842,889	483,913

Stockholders' Equity (Deficit) (Detail Textuals 2) - $ / shares	Sep. 30, 2018	Sep. 30, 2017
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights	$ 1.50
Warrant exercise price 0.01
Class of Warrant or Right [Line Items]
Warrants to acquire stock	3,460	704,019
Class of warrant or right, exercise price of warrants or rights	$ 0.01	$ 0.01
Warrant exercise price 3.00
Class of Warrant or Right [Line Items]
Warrants to acquire stock		82,999
Class of warrant or right, exercise price of warrants or rights		$ 3.00

Convertible Preferred Stock (Detail Textuals) - USD ($)	1 Months Ended			12 Months Ended
Convertible Preferred Stock (Detail Textuals) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Oct. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 07, 2017
Convertible Preferred Stock [Line Items]
Proceeds from issuance of private placement				$ 20,000,000
Proceeds from issuance of Series A convertible preferred stock				21,737,200	$ 3,262,800
Beneficial conversion charge				$ 16,022,963	1,176,743
Value of shares issued in cash					$ 1,503,127
Common stock
Convertible Preferred Stock [Line Items]
Number of share issued					737,817
Value of shares issued in cash					$ 7,378
Conversion of Series A convertible preferred stock into common stock (in shares)				31,572,617
Series A Convertible Preferred Stock
Convertible Preferred Stock [Line Items]
Beneficial conversion charge				$ 597,255
Conversion of Series A convertible preferred stock into common stock (in shares)				(208,836)
Series A Convertible Preferred Stock issued to settle dividends				17,571
BioLexis \| Series A Convertible Preferred Stock
Convertible Preferred Stock [Line Items]
Conversion of Series A convertible preferred stock into common stock (in shares)	208,836
BioLexis \| Series A Convertible Preferred Stock \| Common stock
Convertible Preferred Stock [Line Items]
Convertible preferred stock, shares issued upon conversion	31,572,617
Initial Private Placement \| Purchase agreement \| BioLexis \| Common stock
Convertible Preferred Stock [Line Items]
Stock and warrant issued to acquire shares of common stock					16,750,000
Convertible preferred stock, shares issued upon conversion					37,795,948
Conversion rate per share					$ 0.66
Closing price			$ 1.26			$ 0.90
Initial Private Placement \| Purchase agreement \| BioLexis \| Series A Convertible Preferred Stock
Convertible Preferred Stock [Line Items]
Number of share issued					32,628
Value of shares issued in cash					$ 3,262,800
Dividend rate		10.00%
Initial Private Placement \| Purchase agreement \| BioLexis \| Series A Convertible Preferred Stock And Warrants
Convertible Preferred Stock [Line Items]
Proceeds from issuance of private placement					$ 25,000,000
Number of share issued			217,372
Beneficial conversion charge			$ 15,355,019
Value of shares issued in cash			$ 21,737,200
Terms of warrant			8 years
Series A Convertible Preferred Stock issued to settle dividends				17,571

Convertible Preferred Stock (Detail Textuals 1) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2018	Sep. 30, 2018	Sep. 30, 2017
Convertible Preferred Stock [Line Items]
Recognition Of Beneficial Conversion Feature Upon Issuance Of Convertible Preferred Stock		$ 16,022,963	$ 1,176,743
Series A Convertible Preferred Stock
Convertible Preferred Stock [Line Items]
Series A Convertible Preferred Stock issued to settle dividends		17,571
Recognition Of Beneficial Conversion Feature Upon Issuance Of Convertible Preferred Stock		$ 597,255
Series A-1 Convertible Preferred Stock
Convertible Preferred Stock [Line Items]
Recognition Of Beneficial Conversion Feature Upon Issuance Of Convertible Preferred Stock		$ 70,662
Exchange agreement \| BioLexis \| Series A Convertible Preferred Stock
Convertible Preferred Stock [Line Items]
Number of share issued	58,735
Exchange agreement \| BioLexis \| Series A-1 Convertible Preferred Stock
Convertible Preferred Stock [Line Items]
Number of share issued	58,735
Series A-1 authorized for issuance		200,000
Shares Issued, Price Per Share		$ 100.00
Convertible preferred stock, shares issued upon conversion		8,879,780
Preferred Stock, Dividend Rate, Percentage		10.00%
Liquidation preference description		Liquidation preference payable equals the sum of (A) 550% of the Series A-1 stated value per share plus (B) an amount equal to (x) 550% of any accrued, but unpaid, preferred dividends (as defined in the Certificate of Designation) plus (y) any unpaid participating dividends (as defined in the Certificate of Designation). In the case of a deemed liquidation event (as defined in the Certificate of Designation), the multiplier is increased to 600%.
Percentage of stated value per share of preferred stock liquidation preference payable		550.00%
Percentage of accrued but unpaid preferred dividends		550.00%
Percentage increase in multiplier in case of deemed liquidation		600.00%
Deemed liquidation event description		Additionally, the holder may irrevocably require the Company to redeem the Series A-1 in the event of a deemed liquidation event for the sum of (A) 600% of the Series A-1 stated value per share plus (B) an amount equal to (x) 600% of any accrued, but unpaid, preferred dividends plus (y) any unpaid participating dividends, although such redemption may not be made without the consent of the senior secured noteholders if such notes are outstanding at the time of any such redemption.

Convertible Preferred Stock (Detail Textuals 2) - USD ($)	1 Months Ended	2 Months Ended	12 Months Ended
	Oct. 31, 2017	Jun. 30, 2018	Sep. 30, 2018
Convertible Preferred Stock [Line Items]
Stock issued during period for conversion of convertible securities			$ 14,359,816
Series B Convertible Preferred Stock
Convertible Preferred Stock [Line Items]
Number of stock converted		1,500,000
Stock issued during period for conversion of convertible securities	$ 1,500,000
Conversion of Series A convertible preferred stock into common stock (in shares)	1,500,000
Accrued interest	$ 41,507
Number of stock issued upon conversion	2,112,675	2,112,675

Stock-Based Compensation (Details) - 2015 Equity Incentive Plan - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,985,870	$ 8,571,430
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	19,450	1,001,022
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,966,420	$ 7,570,408

Stock-Based Compensation (Details 1)	12 Months Ended
Stock-Based Compensation (Details 1)	Sep. 30, 2018 $ / shares shares
Number of Shares
Balance at October 1, 2017 \| shares	0
Granted \| shares	1,667,075
Expired/forfeited/cancelled \| shares	(209,930)
Balance at September 30, 2018 \| shares	1,457,145
Vested and exercisable \| shares	30,000
Vested and expected to vest at September 30, 2018 \| shares	1,457,145
Weighted Average Exercise Price
Balance at October 1, 2017 \| $ / shares	$ 0.00
Granted \| $ / shares	0.93
Expired/forfeited/cancelled \| $ / shares	1.10
Balance at September 30, 2018 \| $ / shares	0.93
Vested and exercisable \| $ / shares	1.32
Vested and expected to vest at September 30, 2018 \| $ / shares	$ 0.90
Weighted Average Remaining Contractual Term (Years)
Balance	9 years 8 months 12 days
Vested and expected to vest	1 month 6 days
Vested and expected to vest at September 30, 2018	9 years 8 months 12 days

Stock-Based Compensation (Details 2)	12 Months Ended
Stock-Based Compensation (Details 2)	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate	2.80%
Expected life	6 years
Expected volatility	71.00%
Expected dividend yield	0.00%

Stock-Based Compensation (Details 3) - Performance-based stock units - $ / shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Number of PSUs
Balance	175,530	247,309
Forfeitures	(46,435)	(71,779)
Balance	129,095	175,530
Vested and exercisable	128,660
Vested and expected to vest	129,095
Weighted-Average Base Price Per PSU
Balance	$ 6.27	$ 6.33
Forfeitures	6.43	6.46
Balance	6.25	$ 6.27
Vested and exercisable	6.23
Vested and expected to vest	$ 6.25

Stock-Based Compensation (Details 4) - Restricted stock units - $ / shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Number of RSUs
Balance	939,879	1,094,351
Granted	20,000	615,000
Vested and settled	(842,889)	(483,913)
Forfeitures	(55,881)	(285,559)
Balance	61,109	939,879
Weighted Average Grant Date Fair Value
Balance	$ 18.78	$ 28.61
Granted	1.16	2.11
Vested and settled	18.40	29.05
Forfeitures	17.67	3.14
Balance	$ 19.23	$ 18.78

Stock-Based Compensation (Detail Textuals) - shares	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares, outstanding	72,220,351	24,933,944
2011 Equity Incentive Plan \| Officers, Employees, Consultants and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved for issuance	1,159,420
Common stock, shares, outstanding	129,095
2015 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved for issuance	8,404,023
Number of shares available for grant	5,558,678

Stock-Based Compensation (Detail Textuals 1) - Stock options	12 Months Ended
	Sep. 30, 2018 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value	$ 131,442
Vesting term	10 years
Share price \| $ / shares	$ 0.56
Unamortized expense	$ 726,930
Period for recognition of unamortized expense	3 years 1 month 6 days
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years

Stock-Based Compensation (Detail Textuals 2)	12 Months Ended
Stock-Based Compensation (Detail Textuals 2)	Sep. 30, 2018 USD ($)
Performance-based stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of PSUs	10 years
Condition for early exercise of stock based performance units	Corporate valuation in excess of $400 million
Unamortized expense	$ 1,552
Period for recognition of unamortized expense	4 months 24 days
Performance-based stock units \| After third anniversary from issuance of stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	50.00%
Performance-based stock units \| Fourth anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	50.00%
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized expense	$ 544,691
Period for recognition of unamortized expense	11 months 12 days

Collaboration Arrangements (Detail Textuals) - USD ($)	1 Months Ended				12 Months Ended
Collaboration Arrangements (Detail Textuals) - USD ($)	Jul. 31, 2017	Jun. 30, 2014	Aug. 31, 2013	May 31, 2013	Sep. 30, 2018	Sep. 30, 2017
Huahai Agreement
Revenue Recognition, Milestone Method [Line Items]
Revenue reorganization deferred revenue					$ 714,848	$ 714,848
Deferred revenue					2,323,254	3,038,102
Huahai Agreement \| Substantive milestones
Revenue Recognition, Milestone Method [Line Items]
Milestone payments received				$ 8,500,000
Huahai Agreement \| Non-substantive milestones
Revenue Recognition, Milestone Method [Line Items]
Milestone payments received				$ 7,500,000
IPCA License and Collaboration Agreement
Revenue Recognition, Milestone Method [Line Items]
Milestone payments received					5,000,000
Revenue reorganization deferred revenue					261,072	261,072
Deferred revenue					848,486	1,109,558
IPCA License and Collaboration Agreement \| Substantive milestones
Revenue Recognition, Milestone Method [Line Items]
Milestone payments received			$ 1,000,000
IPCA License and Collaboration Agreement \| Non-substantive milestones
Revenue Recognition, Milestone Method [Line Items]
Milestone payments received			$ 2,400,000
Liomont agreement
Revenue Recognition, Milestone Method [Line Items]
Milestone payments received		$ 1,000,000
Revenue reorganization deferred revenue					236,641	236,641
Deferred revenue					769,083	1,005,724
Liomont agreement \| Substantive milestones
Revenue Recognition, Milestone Method [Line Items]
Milestone payments received		2,000,000			3,000,000
Liomont agreement \| Non-substantive milestones
Revenue Recognition, Milestone Method [Line Items]
Milestone payments received		$ 2,000,000
BioLexis Agreement
Revenue Recognition, Milestone Method [Line Items]
Milestone payments received	$ 1,250,000					2,500,000
Revenue reorganization deferred revenue					1,874,999	2,598,958
Deferred revenue					$ 526,042	2,401,042
Additional milestone payments received	$ 1,250,000					$ 2,500,000

Related-Party Transactions (Detail Textuals) - USD ($)	1 Months Ended	12 Months Ended
Related-Party Transactions (Detail Textuals) - USD ($)	May 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Nov. 30, 2017
Related Party Transaction [Line Items]
Acquired additional laboratory and office equipment		$ 2,781,125	$ 292,086
Sonnet Biotherapeutics, Inc. ("Sonnet")
Related Party Transaction [Line Items]
Estimated gross contract value if all milestones are met	$ 5,100,000
Laboratory equipment under capital leases				$ 115,000
Acquired additional laboratory and office equipment		$ 201,000

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
State tax	$ (3,148,216)	$ 1,500
Foreign tax	(500,000)	500,000
Income tax expense (benefit)	$ (3,648,216)	$ 501,500

Income Taxes (Details 1)	12 Months Ended
Income Taxes (Details 1)	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
U.S. federal statutory rate	(24.30%)	(34.00%)
State taxes, net of federal benefit	(6.90%)	(6.40%)
Sale of New Jersey net operating losses	(7.10%)	0.00%
Net operating loss	8.00%	0.00%
Change in tax rates	66.60%	0.00%
Foreign withholding tax	(1.50%)	1.30%
Permanent differences	(0.60%)	(2.80%)
Foreign tax credits	1.50%	(1.60%)
Research and development credit	(22.90%)	0.00%
Change in valuation allowance	(23.70%)	44.80%
Other	0.10%	0.00%
Effective income tax rate	(10.80%)	1.30%

Income Taxes (Details 2) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Deferred tax assets
Net operating loss carryforwards	$ 39,532,689	$ 48,828,141
Stock-based compensation	10,227,514	14,098,985
Deferred revenue	1,264,069	3,017,238
Research and development credit carryforward	8,491,452	757,701
Foreign tax credits	2,357,309	2,857,309
Accruals and others	605,173	1,539,943
Gross deferred tax assets	62,478,206	71,099,317
Less: valuation allowance	(61,893,959)	(69,902,446)
Deferred tax assets net of valuation allowance	584,247	1,196,871
Deferred tax liability:
Fixed assets	(584,247)	(1,196,871)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Details 3) - USD ($)	12 Months Ended
Income Taxes (Details 3) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 2,352,129	$ 1,854,629
Changes based on tax positions related to the current year	(496,000)	497,500
Balance at end of year	$ 1,856,129	$ 2,352,129

Income Taxes (Detail Textuals) - USD ($)	12 Months Ended
Income Taxes (Detail Textuals) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Operating Loss Carryforwards [Line Items]
Research and development tax credit carryforwards	$ 8,491,452	$ 757,701
Foreign tax credit carryforwards	2,357,309	2,857,309
Increase (decrease) in valuation allowance	(8,000,000)	17,200,000
Recognition of income tax benefits	$ (3,648,216)	$ 501,500
Percentage of decrease in corporate tax rate	21.00%	34.00%
U.S. federal statutory rate	(24.30%)	(34.00%)
Decrease in deferred tax assets	$ (22,400,000)
New Jersey
Operating Loss Carryforwards [Line Items]
Net operating losses	38,470,278
Recognition of income tax benefits	3,150,716
New Jersey net operating loss	68,100,000
Federal
Operating Loss Carryforwards [Line Items]
Research and development tax credit carryforwards	6,600,000
Foreign tax credit carryforwards	2,400,000
Federal net operating loss	164,700,000
State
Operating Loss Carryforwards [Line Items]
Research and development tax credit carryforwards	1,900,000
Foreign
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 400,000

Organization and Operations	12 Months Ended
Organization and Operations	Sep. 30, 2018
Organization And Description Of Business [Abstract]
Organization and Operations	1. Organization and Operations Description of the Business Oncobiologics, Inc. was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with an into a Delaware corporation in October 2015, and in November 2018, changed its name to Outlook Therapeutics, Inc. (“Outlook” or the “Company”). The Company is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex monoclonal antibody (“mAb”) therapeutic for various ophthalmic indications. The Company is based in Cranbury, New Jersey.

Fair Value Measurements (Details) - Fair value measurements recurring basis - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Level 1
Liabilities
Warrant liability	$ 0	$ 0
Level 2
Liabilities
Warrant liability	0	0
Level 3
Liabilities
Warrant liability	$ 1,227,225	$ 2,274,954